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Abstract
Deregulated glucose metabolism is a critical component of cancer growth and survival, as is clinically
evident by FDG-PET imaging of enhanced glucose uptake in tumors. However, the efficacy of direct
pharmacological intervention of glycolysis, a critical biochemical pathway that catabolizes glucose, has
yet to be realized. As an alternative approach, we explored the potential therapeutic value of two
physiological pathways that oppose glucose catabolism in either liver or kidney cancer: gluconeogenesis
and glycogen synthesis, respectively. In liver cancer, I hypothesized that gluconeogenesis could be
stimulated by glucagon signaling to antagonize glycolysis and reduce tumor cell growth. Upon
supraphysiologic overexpression of the glucagon receptor, GCGR, glucagon treatment of the liver cancer
cell line, SNU398, reproducibly decreased cell viability, but without transcriptionally inducing
gluconeogenic gene expression, regardless of the epigenetic landscape. In kidney cancer, we
hypothesized that disrupting glycogen breakdown could prevent release of glucose under stress
conditions and inhibit tumor cell proliferation. Through genetic knockout of key enzymes and carbon-13
labeling, we observed that glycogen metabolism does not affect tumor growth, despite metabolic
utilization of glycogen-derived glucose in culture conditions without glucose. In conclusion, we describe
context-specific approaches to targeting glucose metabolism in cancer that warrant further investigation.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Celeste Simon

Subject Categories
Biochemistry | Cell Biology | Molecular Biology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4413

ASPECTS OF DEREGULATED GLUCOSE METABOLISM IN LIVER AND KIDNEY CANCER
Jason T. Godfrey
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2021

Supervisor of Dissertation

M. Celeste Simon, Ph.D.
Arthur H. Rubenstein, MBBCh Professor

Graduate Group Chairperson

Daniel S. Kessler, Ph.D.
Associate Professor of Cell and Developmental Biology

Dissertation Committee
Marisa S. Bartolomei, Ph.D., Perelman Professor of Cell and Developmental Biology
Sandra W. Ryeom, Ph.D., Associate Professor of Cancer Biology
Donita C. Brady, Ph.D., Harrison McCrea Dickson, M.D. and Clifford C. Baker, M.D. Presidential
Associate Professor
Terence P. Gade, M.D., Ph.D., Assistant Professor of Radiology and Cancer Biology

ACKNOWLEDGMENTS

I’d like to express my gratitude to the following people for all their support:
-

-

My thesis mentor, Dr. Celeste Simon, and Dr. Brian Keith for their teaching,
encouragement, patience, and generosity
Current and previous members of the Simon lab, with a special thanks to the following
people:
o Our lab manager, Michelle Burrows, for her technical guidance and substantial
support
o Former research technicians, Jennifer Finan and Vivek Nimgaonkar, for our
philosophical discussions and being fun to be around
o Senior scientist, Dr. Nicolas Skuli, for his effort and willingness to help with
experiments, analyze data, and brainstorm next steps
o Former graduate student, Dr. Danielle Sanchez, for her advice on the graduate
program and experiments
o Former medical student, Dr. Jun Song, for his unique perspective and friendship
o Former postdoctoral fellow, Dr. Pearl Lee, for giving me feedback and our chats
while walking home
Thesis committee member, Dr. Sandra Ryeom, who really helped clarify and put in
motion the graduation process
Fellow graduate students, Aoi Wakabayashi and Ian Folkert, for being great to talk with
My friend and former neighbor, Dana Lee, who was easy to talk to and got dinner with me
every so often
My longtime friend, Jeff Narewski, for all our great conversations
And lastly, my family: Mom, Dad, Jenna, Kyle, Chris, and our pets, Korra, Luna, Comet,
Cookie, and Chip

The journey to a PhD is a solitary one. The research is your own. The effort is your own. And the
knowledge and skills gained are your own. However, despite these undeniable truths, without the
support of my colleagues, friends, and family, I may very well have not been able to tough it out.
As sincerely as words can convey, thank you all.

ii

ABSTRACT
ASPECTS OF DEREGULATED GLUCOSE METABOLISM IN LIVER AND KIDNEY
CANCER
Jason T. Godfrey
M. Celeste Simon

Deregulated glucose metabolism is a critical component of cancer growth and
survival, as is clinically evident by FDG-PET imaging of enhanced glucose uptake in
tumors. However, the efficacy of direct pharmacological intervention of glycolysis, a
critical biochemical pathway that catabolizes glucose, has yet to be realized. As an
alternative approach, we explored the potential therapeutic value of two physiological
pathways that oppose glucose catabolism in either liver or kidney cancer:
gluconeogenesis and glycogen synthesis, respectively. In liver cancer, I hypothesized
that gluconeogenesis could be stimulated by glucagon signaling to antagonize glycolysis
and reduce tumor cell growth. Upon supraphysiologic overexpression of the glucagon
receptor, GCGR, glucagon treatment of the liver cancer cell line, SNU398, reproducibly
decreased cell viability, but without transcriptionally inducing gluconeogenic gene
expression, regardless of the epigenetic landscape. In kidney cancer, we hypothesized
that disrupting glycogen breakdown could prevent release of glucose under stress
conditions and inhibit tumor cell proliferation. Through genetic knockout of key enzymes
and carbon-13 labeling, we observed that glycogen metabolism does not affect tumor
growth, despite metabolic utilization of glycogen-derived glucose in culture conditions
without glucose. In conclusion, we describe context-specific approaches to targeting
glucose metabolism in cancer that warrant further investigation.
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Chapter 1: Introduction to Glucose Metabolism in Cancer

Portions of this chapter have been adapted from:
(1) Godfrey J, Skuli N, Riscal R, and Simon MC. Glucagon signaling via
supraphysiologic GCGR reduces cell viability without stimulating gluconeogenic
gene expression in the liver cancer cell line, SNU398. Manuscript in preparation.
(2) Hong X, Song J, Godfrey J, Riscal R, Skuli N, Nissim I, and Simon MC. Glycogen
metabolism is dispensable for tumor progression in clear cell renal cell
carcinoma. Nat Metab. 2021. Mar;3(3):327-336. doi: 10.1038/s42255-021-00367x.
(3) Godfrey J. Epigenetic control of the metabolic tumor suppressor FBP1 in liver
cancer. NIH NCI Predoctoral Individual National Research Service Award (F31):
5F31CA239514.
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1.1 Glucose Metabolism and its Role in Cancer
Glucose Metabolism in Normal Physiology
Carbohydrates are one of the major macromolecule nutrients that support life on
Earth, along with fat and protein. In humans, although different cell and tissue types are
differentially adapted to a particular nutrient, for example the neuronal dependency on
sugars due to the exclusion of albumin-bound fat by the blood brain barrier, glucose can
be utilized by all cells (Berg et al, 2002. Biochemistry)1. Glucose is metabolically derived
from the catalytic digestion of complex carbohydrates obtained from the diet, like starch,
and absorbed into the body through the small intestine and passed through the liver
before entering the circulation. Upon pancreatic release of insulin, cells begin expressing
glucose transporters at the plasma membrane to import the acquired glucose and
ultimately fuel many aspects of cell biology and function (Chang et al, 2004)2.
Glucose is trapped within the cytosol of cells via phosphorylation and then is
processed further by different enzymes spanning a multitude of reactions, broadly
referred to as the central carbon pathway, to meet the metabolic demands of a given cell
under an existing set of conditions. Within the central carbon pathway, glucose
catabolism occurs via multiple metabolic machineries that are critical to cell function
(Fig. 1.1; pg. 30). Cytosolic glycolysis and mitochondrial tricarboxylic acid (TCA) cycle
generate energy in the form of adenosine triphosphate (ATP), as well as intermediate
metabolites important for other cellular processes. The pentose phosphate pathway
maintains redox homeostasis, through the regeneration of NAPDH, and produces the
ribose backbone necessary for nucleic acids. The hexosamine biosynthesis pathway
facilitates protein glycosylation, via the conversion of glucose to UDP-GlcNAc, crucial for
cell-to-cell signaling (Zhu and Thompson 2019)3. Glucose can also be used for de novo
2

triglyceride and fatty acid synthesis from glycolytic and TCA intermediates, respectively.
Amino acid synthesis, such as serine, which itself can be incorporated into folate
recycling and one-carbon metabolism, is catalyzed from the catabolism of glucose.
Components of these metabolic pathways may also be present outside of the cytosol
and mitochondria, as studies have shown nuclear localization of enzymes involved in
glycolysis and the tricarboxylic acid cycle (Boukouris et al, 2016; Huangyang and Simon,
2018)4,5.
Due to the ubiquitous nature of glucose in underpinning virtually all aspects of
cellular biochemistry, stress responses and programmed cell death are common fates
during glucose deprivation. Previous work has shown that diminished glucose uptake in
the absence of growth factor stimulation induces mitochondrial-based apoptosis, which
can be ameliorated by increasing the expression of glucose transporters (Vander Heiden
et al, 2001)6. In renal epithelial models of ischemia, glucose removal reduces the
expression of chaperone proteins and increases mRNA levels of unfolded protein
response factors (Bouvier et al, 2012)7. Similar results have been observed in the
context of cerebral and myocardial ischemia, whereby an elevation in glucose
transporters may provide a protective effect (Espinoza-Rojo et al, 2010; Sun et al,
1994)8,9. Due to these vast requirements of glucose, and the lethal consequences of its
deficiencies, strict regulation of blood sugar is critical in maintaining normal cell function.
Systemically, serological glucose homeostasis is controlled by a number of
hormones with complex interactions. Insulin and glucagon, small peptide hormones
secreted by the pancreas, directly regulate circulating glucose by increasing cellular
uptake or production of glucose, respectively. The steroidal family of adrenal glandsynthesized glucocorticoids acts on their nuclear receptors to promote glucose synthesis
3

in the liver (Kuo et al, 2015)10. Epinephrine, a critical neurotransmitter and hormone part
of the fight or flight response, works together with glucagon and glucocorticoids to
amplify their effects on glucose metabolism (Sherwin and Sacca, 1984)11. In fact,
epinephrine binds a G-coupled protein receptor, β2-adrenergic receptor, mechanistically
similar to glucagon (discussed below), whose expression levels correlate with a
gluconeogenic response to epinephrine (Kim et al, 2009)12. Pharmacologic
administration of active thyroid hormone, triiodothyronine (T3), in human subjects
resulted in an 18% increase in blood glucose levels, accompanied by a 30% increase in
gluconeogenic conversion of labeled alanine to labeled glucose (Sandler et al, 1983)13.
Other hormones, like somatostatin (Del Guercio et al, 1976)14 and glucagon-likepeptide 1 (MacDonald et al, 2002)15 produced in the gut, and adipocyte-derived leptin
(Koch et al, 2010)16 can induce glucose uptake, reduce hyperglycemia, and help
overcome insulin resistance in models of diabetes. Inhibition of myostatin, which is
secreted by myocytes to block skeletal muscle hypertrophy, was shown to increase
mRNA levels of genes involved in glucose uptake, suggesting myostatin may also
contribute to glucose homeostasis (Coleman et al, 2016)17. Intrinsically, cells also
possess mechanisms to effectively sense glucose availability by activating proteins
specifically in response to relative ratios of ATP:AMP, whereby higher amounts of AMP
can stimulate AMP kinase to increase glucose uptake and thereby restore energy levels
(Yuan et al, 2013)18.
As an extension of glucose regulation at both an organismal and cellular level,
glucose is also saved for future utilization in two ways when energy and nutrients are
plentiful. The direct method of glucose storage comes in the form of glycogen (discussed
later), which is comprised of a core protein, glycogenin, surrounded by a branching
4

network of covalently-bound glucose molecules. Glycogen constitutes a major
component of skeletal muscle, where it is rapidly depleted to support muscle activity,
and the liver, where it is broken down into glucose and released into the circulation
during periods of fasting. Excess glucose can also be indirectly converted into fatty acids
through hepatic lipogenesis, and stored in adipose tissue as triglycerides (Glimcher and
Lee, 2009)19.
Overall, glucose metabolism is central to human biology. The widely pleotropic
purposes of glucose, in conjunction with multiple mechanisms to regulate its serological
and intracellular concentrations, highlights the paramount role of glucose metabolism in
normal physiology. Unsurprisingly, in pathological states, abnormal glucose utilization
can also be critical in promoting disease onset and severity.
Examples of Glucose Metabolism in Diabetes and Hereditary Diseases
Aberrant glucose metabolism, either amplified or dampened, can result in or
contribute to a number of pathologies. In the case where glucose uptake and/or
catabolism is enhanced, this can sustain diseases characterized by abnormal cell
growth, i.e. cancer (discussed later). In contrast, when cells lack adequate capability to
import glucose from the circulation, usually a consequence of insulin resistance, this can
effectuate hyperglycemia and diabetic symptoms. High blood sugar concentration can
even lead to pathological osmolality gradients, whereby water and other solutes diffuse
out of cells to maintain equilibrium. This chemical phenomenon alone can result in a
wide range of deleterious effects, including hypertension, hypertonic cell states, and
electrolyte imbalances due to elevated renal reabsorption of glucose and sodium (Liamis
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et al, 2014)20. Therefore, understanding mechanisms driving deregulated glucose
metabolism is critical to developing new therapeutics or preventing disease onset.
Notably, insulin resistance is a major mechanistic driver of both types of diabetes,
which collectively accounts for as much as 10.5% of the population in the US (National
Diabetes Statistics Report, 2020)21. Whereas type I diabetes involves an autoimmune
response to insulin-secreting β-cells of the pancreas, which effectively depletes insulin,
type II diabetes is generally characterized by poor long-term nutrition, such as high fat
and/or sugar consumption, which is thought to induce states of insulin insensitivity
through multiple mechanisms. One theory postulates that high carbohydrate intake
forces continued overproduction of insulin that induces ER-dependent stress responses,
resulting in the loss of β-cell integrity and insulin capacity (Muoio and Newgard, 2008)22.
Moreover, this reduced insulin production can be exacerbated by the consequential
relaxation of negative feedback on glucagon signaling, which is normally opposed and
shut off by insulin secretion during food intake, leading to even greater circulating
glucose and hyperglycemia (Kawamori et al, 2009; Gromada et al, 2009)23,24. In fact,
drugs targeting effectors of glucagon signaling are in development for the treatment of
type II diabetes (discussed later).
Insulin resistance, hyperglycemia, and the inability of cells to import glucose have
numerous pathophysiological ramifications, including diabetic neuropathy (Said, 2007)25
and ketoacidosis (Dhatariya et al, 2020) 26. Tissues that express insulin-dependent
glucose transporter 4 (GLUT4), such as skeletal muscle and adipose tissue, are
particularly sensitive to insulin resistance (Yang et al, 2001)27. Impaired glucose uptake
in myocytes can induce sarcopenia through stabilization of the transcription factor,
Krüppel-like factor 15 (Hirata et al, 2019)28, which itself can stimulate GLUT4 expression
6

(Gray et al, 2002)29, suggesting mechanisms of defective negative feedback. Likewise,
when insulin cannot suppress fat lipolysis, inflammatory conditions via M1 macrophage
polarization can occur due to adipocyte-secreted factors (Odegaard and Chawla,
2013)30. Insulin resistance can also have glucose-independent effects, evident in the
vasculature whereby deficient insulin signaling can disrupt angiogenesis, vasodilation,
and pericyte integrity (Escudero et al, 2017)31, potentially contributing to atherosclerosis
(Rask-Madsen et al, 2010)32 and ischemia (He et al, 2006)33.
While significantly less common than adult onset type II diabetes, there are also a
wide variety of hereditary disorders characterized by dysfunctional glucose metabolism,
known as inborn errors of metabolism (El-Hattab, 2015)34. These pathologies are due to
specific, often autosomal recessive, mutations in genes involved in carbohydrate
processing. One example particularly relevant for the work described in this dissertation
is the inactivating mutation of the gene, glucose-6-phosphatase catalytic subunit alpha
(G6PC), which can result in the pathological accumulation of hepatic glycogen,
contribute to liver inflammation, and increases the risk for liver cancer (Chou and
Mansfield, 2008)35.
Glucose Metabolism in Cancer
While diabetes and some genetic disorders of glucose metabolism are major risk
factors for cancer development, the pathological nature of glucose metabolism is reverse
in the context of cancer. Rather, tumor cells display increased uptake of glucose, which
can be diagnostically distinguished from surrounding normal tissue via
fluorodeoxyglucose PET imaging (Zhu et al, 2011)36. Oncogenic drivers and hyperactive
mitogenic pathways, such as Ras, PI3K/Akt, c-Myc, and HIFs can induce the
7

transcription of glucose transporters and ultimately contribute to an elevated import of
glucose (Ancey et al, 2018)37. Loss of tumor suppressor genes, such as TP53, can also
increase the uptake and utilization of glucose in cancer cells (Levine and Puzio-Kuter,
2010)38.
Although recent studies suggest intratumoral myeloid cells may be mostly
responsible for the increased consumption of glucose (Reinfeld et al, 2021)39, elevated
catabolism of glucose is commonly measured in both human and murine tumors, such
as in patients with lung cancers (Hensley et al, 2016)40 and mouse models of liver
cancer (Mendez-Lucas et al, 2017)41. In addition to providing the cell with energy,
enhanced glycolysis, as well as oxidation of glucose, are thought to critically support
processes necessary for continual anabolic growth in tumors (Lunt and Vander Heiden,
2011)42. Examples of such processes include the reinforcement of antioxidant recycling
and mitigating reactive oxygen species which can be facilitated by increasing metabolic
flux of glucose through the pentose phosphate pathway (Patra and Hay, 2014)43. Tumor
vascularity is another process affected by glucose metabolism, as pyruvate
dehydrogenase kinase, a glycolytic enzyme that increases the reduction of pyruvate to
lactate, has been shown to increase tumor vessel density without inducing standard
angiogenic factors, such as VEGF, in Wnt-driven models of colon cancer (Pate et al,
2014)44.
In the context of invasiveness and metastasis, prostate cancer cells with greater
migratory ability displayed enhanced glycolytic capacity (Shiraishi et al, 2015)45.
Elevated glucose import and glycolysis can also contribute to epithelial-to-mesenchymal
transition (EMT), which correlates with tumor aggressiveness (Masin et al, 2014)46.
Conversely, transcription factors that repress EMT, such as Snail, have been reported to
8

redirect the increased uptake of glucose away from bioenergetics and towards the
pentose phosphate pathway under stress conditions, thereby promoting tumor cell
adaptability (Kim et al, 2017)47. In a similar vein, a single-cell metabolomics analysis of
circulating tumor cells (CTCs), derived from an in vivo breast cancer model, suggested a
subset of CTCs displayed greatly increased rates of glucose uptake relative to the
parental cell line (Sasportas et al, 2014) 48.
In regards to the tumor microenvironment, transcriptomic studies in breast cancer
identified a positive association between glycolytic gene expression and inflammation
pathways, such as IL-17 signaling (Li et al, 2020)49. Interestingly, this study also
revealed that high glycolytic gene expression associated with decreased cAMP signaling
pathway genes, some of which regulate gluconeogenesis (discussed later). Additionally,
upregulated tumor glycolysis is also thought to promote immune evasion via lowering
extracellular pH due to increased lactic acid export, which favors the differentiation of
tumor-associated macrophages and fibroblasts (Kareva and Hahnfeldt, 2013)50. Gastric
tumor cells with high metastatic capacity have been shown to alter the glucose
metabolism of adjacent fibroblasts themselves, inducing up to a 30% increase in rate of
lactate production (Kogure et al, 2020) 51.
Therefore, not only does amplified glucose uptake and catabolism fuel cell growth,
as one would expect, it also contributes to many other areas of tumor biology. Targeting
glycolysis and disrupting glucose catabolism, specifically in tumor tissue, with
pharmacological agents is a rational approach to overall treatment strategies for cancer
patients (Hamanaka and Chandel, 2012)52.

9

1.2 Inhibition of Glucose Metabolism in Cancer
Glycolysis
The clinical efficacy of direct glycolytic inhibitors remains unclear, as drugs targeting
the enzymes that catalyze glucose catabolic reactions exist largely in the experimental
phase (Akins et al, 2018)53. However, some compounds have been briefly evaluated in
clinical trials. 2-deoxyglucose (2DG), a metabolically inert analog of glucose has been
shown to reduce cancer cell viability through multiple mechanisms (Pelicano et al, 2006;
Ralser et al, 2008)54,55, especially in combination with oxidative phosphorylation
inhibition (Sahra et al, 2010)56 or under hypoxic conditions (Liu et al, 2001; Maher et al,
2007)57,58. However, as a monotherapy, 2DG did not offer any significant benefit to
prostate cancer patients in a phase II clinical trial (NCT00633087). Another attractive
class of anti-glycolytic compounds analyzed are inhibitors of lactate dehydrogenase
(LDH). While many LDH inhibitors suffer from off-target effects, a recent study utilizing a
LDHA/B isoform-specific molecule, NCI-006, showed significant in vivo efficacy in
blocking pyruvate to lactate reduction, as well as decreasing tumor proliferation in a
pancreatic adenocarcinoma xenograft model (Oshima et al, 2020)59. Additionally, an
inhibitor of the lactate exporter, monocarboxylate transporter 1, is currently in a phase I
clinical trial in lymphoma patients (NCT01791595).
Pentose Phosphate Pathway
The first and rate-limiting step of the pentose phosphate pathway is catalyzed by the
enzyme, glucose-6-phosphate dehydrogenase (G6PDH). Importantly, this enzyme also
produces NAPDH, a critical cofactor in antioxidant and lipid synthesis, thereby making it
an ideal target for blocking the anabolic benefits of the pentose phosphate pathway. One
10

inhibitor of G6PDH, dehydroepiandrosterone (DHEA), has been shown to
noncompetitively block the reverse reaction mediated by G6PDH (Gordon et al, 1995)60
and increase cell death in cancer models (Fang et al, 2016)61. Additionally, DHEA has
been employed clinically for treatment of cancer, especially in breast cancer and the
mitigation of complications due to breast cancer (NCT04705883). However, it is unclear
whether DHEA can attentuate disease progression or promote survival. Moreover,
DHEA is a precursor molecule to the sex hormones, and as such it has a wide range of
effects, including anti-inflammatory and gender-specific fat composition (Morales et al,
1998)62, which raise questions about its specificity for G6PDH. More recently identified
inhibitors, such as the plant-based polydactin (Mele et al, 2018)63 and a chemically
modified aminoquinazolinone, G6PDi-1 (Ghergurovich et al, 2020)64, have also shown
effectiveness at reducing G6PDH activity and disrupting the pentose phosphate pathway
in the context of cancer and the immune system. Further experimentation and more
clinical trials could incorporate these compounds, or their bioavailable derivatives, into
cancer therapy strategies.
Hexosamine Biosynthesis Pathway
The end product of the hexosamine pathway is the molecule uridine diphosphate Nacetylglucosamine (UDP-GlcNAc), which is utilized by enzymes to modify proteins,
lipids, and amino sugars with GlcNAc groups. These glycosylations are critical for many
aspects of cell biology, such as the cytoskeletal and nuclear architecture, extracellular
matrix remodeling, intracellular signaling and enzyme activity, and the glycocalyx.
Perhaps unique to this pathway is that the synthesis of UDP-GlcNAc requires not only
glucose, but also glutamine, acetyl-CoA, and UTP, and therefore can theoretically be
regulated in complex ways. Nevertheless, the initial rate limiting step is catalyzed by
11

glutamine-fructose-6-phosphate amidotransferase 1 (GFAT1). An analysis in pancreatic
cancer patients reveals that high expression of GFAT1 correlates with decreased overall
survival rates and increased lymph node metastasis (Yang et al, 2016) 65. Intriguingly,
preclinical trials of an inhibitor to GFAT1, 6-diazo-5-oxo-L-norleucine (DON), may have
synergize with the anti-PD1 immunotherapy to reduce tumor burden and enhance
survival in pancreatic cancer models (Sharma et al, 2020)66. Additionally, inhibitors of the
enzyme that functionally transfers GlcNAc to its target, O-linked N-acetylglucosamine
transferase (OGT), are being developed and have shown efficacy in eliminating
leukemia cells in both subcutaneous and circulating models (Asthana et al, 2018)67.
While hexosamine blockade is a rationale therapeutic target, more efforts are needed to
translate GFAT1 or OGT drugs into the clinic.
Glycerol-3-Phosphate Synthesis
Lipid droplets are organelles primarily composed of cholesterol esters and
triacylglycerols encased by a phospholipid monolayer. Physiologically, lipid droplets
serve as a source of fatty acids, and by extension energy, primarily in adipocytes.
However, emerging data has revealed that lipid droplets are increased in a variety of
cancers, such as glioblastoma (Wu e. al, 2020)68, renal cell carcinoma (Du et al, 2017)69
and metastatic pancreatic adenocarcinoma (Rozeveld et al, 2020)70, and play a vital
component to cancer cell progression through a multitude of mechanisms (Cruz et al,
2020)71. Breast tumor cells can even induce catabolism of lipid droplets in fatty liver
cells, and possibly uptake the released fatty acids to facilitate metastasis (Li et al,
2020)72. Therefore, inhibiting de novo lipogenesis to reduce lipid droplet formation, and
subsequent utilization, is a potential therapeutic strategy in cancer. Triacylglycerol and
phospholipid synthesis requires the production of glycerol-3-phosphate, which forms the
12

basis of the polar head group. Glycerol-3-phosphate dehydrogenase (GPD) is the
enzyme that catalyzes glycerol-3-phosphate from the glycolytic metabolite,
dihydroxyacetone phosphate. Mixed data on GDP1 exists, whereby in glioblastoma it
may be involved in stem cell maintenance (Rusu et al, 2019)73, but in other models, such
as lung and prostate, ectopic expression of GDP1 together with metformin inhibited
xenograft growth (Xie et al, 2020)74. However, enzymes that first esterifies glycerol-3phosphate with fatty acid groups, glycerol-3-phosphate acyltransferases (GPAT), have
been shown to promote tumor progression in ovarian (Marchan et al, 2017)75 and liver
(Ellis et al, 2012)76 cancer. While an inhibitor with broad activity against GPAT enzymes,
FSG67, has been demonstrated to decrease fat mass in preclinical murine models of
obesity (Kuhajda et al, 2011)77, it remains unknown if this compound is effective in
cancer or whether it is translatable to human patients.
De Novo Serine Production
The epigenetic landscape is heavily studied field in tumor biology, particularly DNA
and histone methylation, and is widely accepted to be dysregulated in cancer. In the
context of metabolism, S-adenosylmethionine (SAM) is the substrate utilized to transfer
methyl groups to chromatin. SAM can be synthesized from methionine through the
reactions of multiple pathways, collectively referred to as one-carbon metabolism.
Specifically, serine is used as a substrate to generate methyl-tetrahydrofolate, which
then goes on to transfer its methyl group to homocysteine, thereby recycling methionine
and SAM. Previous studies have revealed serine auxotrophy in colorectal cancer
models, whereby specialized diets absent in serine or glycine reduced tumor burden
(Maddocks et al, 2017)78. Conversely, other cancers able to produce serine on their own
from glucose or gluconeogenic sources are sensitive to inhibition of enzymes involved in
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de novo serine biosynthesis. The rate-limiting enzyme, phosphoglycerate
dehydrogenase (PHGDH), has been shown to increase glucose-derived serine in
tumors, as well as accelerate tumorigenesis in genetically engineered mouse models of
both triple negative breast cancer and BRAFV600E melanoma (Sullivan et al, 2019)79.
Additionally, the anti-p53 oncogene, MDM2, can stimulate gene expression of enzymes
involved in serine biosynthesis through direct chromatin interaction (Riscal et al, 2016) 80.
Moreover, serine-derived glutathione redox is perturbed upon MDM2 shRNA depletion in
non-small cell lung cancer cells, which correlates with enhanced sensitization to dietary
serine deprivation in xenograft models. Therefore, inhibitors targeting PHGDH are a
rational approach to attenuating serine metabolism in cancer patients. At this time,
PHGDH drugs remain under investigation in discovery and preclinical phases
(McNamee et al, 2021)81.
TCA Cycle and Oxidative Phosphorylation
The TCA cycle comprises of a cyclic series of reactions canonically designed to burn
off glucose carbons, and thereby generate carbon dioxide, whilst transferring electrons
to molecular oxygen via coupling to 4 transmembrane protein complexes of oxidative
phosphorylation. Importantly, the electron transport chain generates a pH and proton
concentration gradient which ultimately drives the energetic production of ATP by ATP
synthase (also referred to as complex V). In terms of energy synthesis, production of key
secondary metabolites, and its cellular role as a hub for interconnected pathways and
processes, disrupting the TCA cycle and/or oxidative phosphorylation remains a highly
attractive target in cancer. Since the TCA cycle can be fed carbon from not only glucose
but amino acids, like glutamine, and fatty acids through -oxidation, many potential
targets exist that could impair proper mitochondrial activity.
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Perhaps the most widely used drug is metformin, which has traditionally been used
to treat diabetes and experimental data has suggested numerous mechanisms to
explain its ability to improve blood sugar via effects on the mitochondria. Specifically,
metformin can disrupt oxidative phosphorylation (Madiraju et al, 2014) 82, induce calciumdependent mitochondrial dysfunction (Loubiere et al, 2017)83, activate AMPK to regulate
mitochondrial fission (Wang et al, 2019)84, and may alter the electron-coupling of
complex I (Cameron et al, 2018)85. However, many of the precise mechanisms of
metformin are still under investigation, despite its widespread use in diabetes. Metformin
has been tested and is currently in clinical trials for cancer (NCT02028221) but its
efficacy as a single agent or in combination with other drugs remains unclear.
Newer, more specific compounds that target individual mitochondrial enzymes are
being developed. One such drug in phase I clinical trials for cancer, IACS-01079, blocks
complex I activity and reduces experimental models of glioblastoma and leukemia
(Molina et al, 2018)86. Inhibitors for another protein, mitochondrial pyruvate carrier
(MPC), which is effectively the initial step in the TCA cycle, are also under development
as an adjuvant therapy to radiation in cancer (Corbet et al, 2018) 87. Lastly, an emerging
cancer target is glutamine metabolism, which is an important component of sustaining
the TCA cycle through -ketoglutarate. CB-839 is an inhibitor of glutamine catabolism
that has shown antitumor efficacy in sarcoma models (Lee et al, 2020)88 and is currently
being tested in phase II clinical trials (NCT04265534).
In summary, a variety of potent and specific compounds against enzymes involved in
pathways of glucose metabolism are being considered for cancer treatment. With the
discovery and clinical optimization of these drugs still ongoing, another potentially
effective approach in antagonizing glucose catabolism as a whole process could be by
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stimulating glucagon-dependent gluconeogenesis (Khan et al, 2015)89 or disrupting
glycogen homeostasis (Khan et al, 2020)90.

1.3 Glucagon, Gluconeogenesis, and Glycogen
Glucagon
Upon fasting conditions, the body maintains glucose homeostasis via two processes:
glycogenolysis and gluconeogenesis (Fig. 1.2; pg. 31). Glycogenolysis releases stored
glucose, whereas gluconeogenesis synthesizes glucose from non-carbohydrate sources,
such as lactate, alanine, and fatty acids. Both pathways mainly occur in the liver,
followed by the kidney, and are directly regulated by circulating hormones. Normally,
rates of hepatic glycogen breakdown and gluconeogenesis are elevated in response to
glucagon, a major regulator of blood glucose homeostasis (Ahren, 2015)91. The gene
encoding glucagon, GCG, is initially transcribed and translated into a pre-proglucagon
molecule that is catalytically cleaved in a tissue specific manner into at least 4 distinct
small peptides, whereby the glucagon isoform is secreted by exocrine -cells of the
pancreas upon a complex network of metabolic, hormonal, and neurological stimuli
(Elliot et al, 2015)92.
Canonically, falling blood sugar triggers glucagon-dependent metabolic rewiring in
the liver to promote glucose production and secretion (Gerich et al, 1976; Ramnanan et
al, 2011)93,94. Specifically, hepatic β-oxidation of hydrolyzed fatty acid stores, alanine
uptake and ALT-mediated conversion to pyruvate, and glutamine anaplerosis via GLS2
are all upregulated by glucagon signaling; all of which provides the carbon and energy
necessary for de novo glucose production (Habegger et al, 2010; Adeva-Andany et al,
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2019; Miller et. al, 2018)95-97. Other encoded peptides are synthesized via tissue-specific
alternative cleavage, such as glucagon-like-peptide 1 (GLP-1), which is produced in both
α-cells and enteroendocrine cells of the gut (Ellingsgaard et al, 2011)98. Interestingly,
GLP-1 has largely the opposite effects of glucagon, increasing insulin and regulating
satiation (Shah and Vella, 2014)99.
GCG-null mice develop normally, despite low blood glucose levels in 2 week old
mice, which is largely normalized at 2-3 months of age (Hayashi et al, 2009) 100. This
suggests that other hormones and factors may compensate for a lack of glucagon, and
its related peptides, over time. In humans, no mutations in GCG in any diseases have
been identified. Glucagon is deployed therapeutically for restoring blood glucose during
life-threatening instances hypoglycemia (Kedia, 2011)101, but not as a routine treatment.
Nevertheless, glucagon acts as a ligand that binds to the G-coupled glucagon receptor
(GCGR), a class B G-coupled protein receptor that, upon ligand interaction, primarily
leads to the dissociation of Gs alpha subunits that stimulate adenylyl cyclase activity and
produces cyclic AMP (cAMP) (Qiao et al, 2020)102.
Previous studies have demonstrated that GCGR-deficient mice are viable and
display lower levels of circulating glucose levels similar to GCG-null mice (Gelling et al,
2003)103. However, loss of GCGR results in elevated glucagon secretion, most likely due
to a lack of negative feedback, which can lead to a rare type of pancreatic
neuroendocrine tumor characterized by α-cell hyperplasia, increased serum amino acid
concentrations, and enhanced mammalian target of rapamycin activity (Solloway et al,
2015; Smith et al, 2020)104,105. A small percentage of GCGR missense mutations exist in
humans that create variants with reduced glucagon binding affinity and correlate with
insulin-independent diabetic symptoms (Hager et al, 1995)106. Conversely, in patients
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with predominantly insulin-dependent diabetes (and therefore require insulin injections),
antibody and antisense RNAi-based antagonists of GCGR are under clinical
investigation in their capacity to combat hyperglycemia, either as single agents or in
combination with other therapeutics, such as metformin (Scheen et al, 2017; Morgan et
al, 2019; Wang et al, 2021)107-109.
The functional result of glucagon-GCGR-Gs-adenylyl cyclase interaction is the
generation of the secondary messenger: cyclic AMP (cAMP) (Miller et al, 2013)110.
Canonically, cAMP binds to the regulatory subunits of protein kinase A (PKA), initiating
the auto-phosphorylation of its catalytic domains (Smith et al, 2017) 111. In the short term,
active PKA can phosphorylate a number of targets, such as phosphorylase kinase
(Brushia and Walsh, 1999)112 to activate glycogen breakdown and release stored
glucose (Magnusson et al, 1995)113. PKA has also been demonstrated to enhance
lipolysis, particularly in adipocytes and hepatocytes; however, the mechanism remains
unclear. Some evidence suggests PKA can directly phosphorylate and inactivate AMPK
at Ser 173 (Djouder et al, 2010)114, which may amplify its ability to activity hormonesensitive lipase (HSL) (Duncan et al, 2007)115. Conversely, another study reported
AMPK impeded lipogenesis through its phosphorylation and inhibition of acetyl-CoA
carboxylase 1 (ACC1) (Peng et al, 2012)116, a rate limiting enzyme in the early steps of
fatty acid synthesis.
In addition to potential involvement of Gq-phospholipase C-mediated Ca+2 release
downstream of GCGR (Xu and Xie, 2009)117, PKA can also raise intracellular Ca+2 levels
via phosphorylation of IP3R calcium channels in the ER (Wang et al, 2012)118. Similar to
cAMP, cytosolic calcium allosterically interacts with the inhibitory domains of many
enzymes, including the phosphatase calcineurin and the kinase holoenzyme,
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Ca+2/calmodulin-dependent protein kinase II (CAMKII) (Meyers et al, 2017)119. Indeed,
knockouts of specific CAMKII targets, such as hepatic lipases (ATGL), significantly
reduced plasma glucose concentrations following glucagon treatment in mice (Perry et
al, 2020)120.
In the long term, PKA and CAMKII function lead to activation of transcription factors
that control gluconeogenic and lipolytic gene expression, such as cAMP response
element-binding protein (CREB), forkhead box protein O1 (FoxO1), and peroxisome
proliferator-activated receptor α (Herzig et al, 2001; Ozcan et al, 2012; Longuet et al,
2008)121-123. Increased gluconeogenic gene expression, integrated with enhanced fatty
acid oxidation, rewires hepatic metabolism to synthesize and export glucose from noncarbohydrate sources (i.e. amino acids and lipids) in an energy-demanding process (Rui,
2014)124. Notably, muscle-secreted lactate and alanine are oxidized and deaminated into
pyruvate in hepatocytes, respectively, followed by pyruvate carboxylase (PC)-mediated
catalysis into oxaloacetate (OAA). OAA serves as a critical intermediate metabolite
connecting the TCA cycle with gluconeogenesis (Cappel et al, 2019)125. In effect,
glucagon signaling contributes to blood sugar homeostasis by raising systemic glucose
concentration via liver-dependent glycogenolysis and gluconeogenesis.
Lastly, important to consider are the effects of other hormones on potentiating
glucagon signaling and negative feedback mechanisms to maintain homeostasis.
Glucocorticoids, thyroid hormone, and catecholamines can amplify the effects of
glucagon, as previously mentioned. Conversely, cAMP and PKA signaling is diminished
by activation of phosphodiesterases, which can be stimulated by insulin (Degerman et
al, 1997)126 and CAMKII (Mika et al, 2015)127. Surface expression of GCGR is regulated
by endocytic internalization, which facilitates glucagon-mediated deubiquitination to
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hypothetically stabilize downstream signaling (Kaur et al, 2020) 128. Additionally, in
immunoprecipitation experiments, GCGR may directly associate with a 14-3-3 protein
(YWHAB) that slightly reduces its activity (Ji et al, 2021)129. Systemically, upon
glucagon-induced hepatic glucose production, the pancreatic β cells begin to secrete
insulin, which then blocks glucagon signaling as described above, and ultimately
accounts for the physiological cycling of insulin and glucagon signaling in response to
states of feeding or fasting, respectively.
Gluconeogenesis
Three irreversible gluconeogenic enzymes are required for full pathway engagement:
phosphoenolpyruvate carboxykinase (PCK), fructose-1,6-bisphosphatase (FBP), and
glucose-6-phosphate catalytic subunit C (G6PC). Physiologically, the pathway begins in
oxygenated, periportal hepatocytes where glucagon signaling opposes Wnt/β-catenin
transcriptional programs to stimulate gluconeogenic and lipolytic gene expression
(Halpern et al, 2017; Cheng et al, 2018) 130,131. These genes initiate a metabolic
machinery that converts adipocyte-derived fat stores or anaerobic byproducts of muscle
activity into precursors for glucose production, such as acetyl-CoA and pyruvate,
respectively. Pyruvate in particular is then shuttled into the mitochondrial matrix via
mitochondrial pyruvate carrier proteins, whereby it can enter the TCA cycle as acetylCoA or oxaloacetate (OAA) directly, by pyruvate dehydrogenase complex (PDC) or
pyruvate carboxylase (PC), respectively.
Following metabolite shuttling via antiporters between the mitochondrial matrix and
intermembrane space, cytosolic OAA is then decarboxylated and phosphorylated in a
GTP-dependent reaction by PCK1 to produce phosphoenolpyruvate (PEP), the first rate
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limiting step of gluconeogenesis. Important to note, based on the relative NADH redox
state of the cell, PEP can also be generated directly in the mitochondria by PCK2.
Nevertheless, PEP is a glycolytic metabolite that can now undergo a series of reversible,
upward steps to synthesize fructose-1,6-bisphophate, by FBP1, and finally glucose, by
G6PC. Notably, these last reactions of dephosphorylation do not generate ATP, but
rather free inorganic phosphate, which can be utilized for the endergonic reaction of
cellular respiration upon re-feeding. This resulting unmodified, de novo glucose diffuses
out of the cell through facultative glucose transporters, namely GLUT2 in hepatocytes
(Karim et al, 2012)132, whereby it ultimately contributes to maintaining blood sugar
homeostasis.
All of the gluconeogenic enzymes are under investigation for potential roles in tumor
suppression, as many cancer cells favor high rates of glucose import and glycolysis,
rather than glucose production and export (Wang and Dong, 2019)133. Previous studies
have identified anti-tumorigenic roles of FBP1 in a variety of cancers (Jin et al, 2017; Lu
et al, 2020; Li et al, 2016)134-136, particularly in clear cell renal cell and hepatocellular
carcinomas (Li et al, 2014; Li et al, 2020)137,138. Data on PCK1 has been mixed, whereby
PCK1 overexpression accelerates colorectal xenograft growth (Montal et al, 2015) 139 but
then may antagonize hepatoma proliferation (Xiang et al, 2021) 140, suggesting contextual
roles of PCK1 for a given tumor type and metabolic stress. For G6PC, although some
data has suggested it can protect glioblastoma cells from 2-deoxyglucose (Abbadi et al,
2014)141, G6PC has mostly been characterized in glycogen storage disease type Ia, in
which patients have dysfunctional, somatic mutations in GP6C (Lei et al, 1996) 142.
Interestingly, glycogen storage disease does predispose and correlate with patients
developing liver cancer (Kishnani et al, 2009) 143, although this may be more due to
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chronic inflammation from hepatomegaly and liver damage rather than strictly adverse
metabolic effects (Kim et al, 2017) 144.
Glycogen
The biochemical function of glycogen is to store glucose when ATP levels are high
and release glucose, in the form of glucose-1-phosphate, through a process known as
glycogenolysis when ATP levels decline (Adeva-Andany et al, 2016)145. Briefly, glycogen
is constructed via a core protein unit, glycogenin, from which glucose molecules are
covalently linked together through linear α(1-4) and branched α(1-6) bonds by glycogen
synthases (GYS), and reciprocally degraded via hydrolysis by glycogen phosphorylases
(PYG) to yield both monosaccharides (glucose) and polysaccharides (maltose, etc.).
This dynamic process is tightly regulated on multiple levels in mammals, both
systemically by the insulin/glucagon axis and intracellularly through energy-sensing
mechanisms, such as AMPK and HIF-1α. All of these factors converge on the regulation
of GYS and PYG, pushing the equilibrium to either glycogen synthesis or breakdown.
Specifically, the activities of GYS and PYG are both controlled posttranslational
modifications, particularly phosphorylation.
In normal human physiology, the vast majority of glycogen resides in two tissue
types: the liver, and high-energy consuming organs, including skeletal muscle and brain
(Cali et al, 2019)146. Upon temporary drops in blood sugar levels, such as during sleep,
hormonal cues immediately stimulate hepatic glycogenolysis, accounting for as much as
50% of the increase plasma glucose concentrations (Gerich, 2010)147. The kidney, while
contributing mainly through gluconeogenesis, does not substantially contain glycogen,
let alone provide glucose via glycogen breakdown (Stumvoll et al, 1997) 148.
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Comparatively, tissues that require high energy levels, and therefore readily available
glucose, lack the enzyme G6PC, which prevents glycogen-derived glucose from
diffusing out of the cell. Other cell types have been reported to utilize glycogen as well,
such as macrophages. In fact, a recent study in mice showed that LPS-stimulated
inflammatory factors can be suppressed with an inhibitor of glycogenolysis (Ma et al,
2020)149. Cell non-autonomous cases of glycogen catabolism have also been described,
such as co-culture experiments of cancer-associated fibroblasts inducing the breakdown
of glycogen in ovarian cancer cells (Curtis et al, 2019)150.
In tumors, increased glycogen abundance has been widely reported across a variety
of subtypes, including kidney, suggesting that glycogen may confer some metabolic
benefit within the tumor microenvironment (Rousset et al, 1981)151. However, another
hypothesis could be that as tumor cells uptake more glucose, all metabolic processes
downstream are relatively increased compared to adjacent normal tissue, but glycogen
is simply a collateral metabolite. Another theory supported by previous studies proposes
that intratumoral hypoxia can promote glycogen accumulation (Shen et al, 2010; Dauer
and Lengyel, 2019)152,153. This oxygen-dependent effect may be more relevant for cancer
cell viability, as coordinating glucose catabolism with tumor vascularization may then
optimize production of ATP and TCA cycle intermediates, whilst maintaining
mitochondrial integrity. Without adequate oxygen as the final electron acceptor,
unregulated oxidative phosphorylation can become uncoupled with the electron transport
chain, leading to potentially toxic levels of reactive oxygen species (Chiu et al, 2019)154.
Therefore, glycogen metabolism in cancer may be both irrelevant and functionally
necessary depending on the precise spatiotemporal nutrient conditions with a tumor
microenvironment.
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Glucagon signaling, gluconeogenesis, and glycogen processing are all interwoven
components of glucose metabolism. In cancer, despite advances in our understanding of
the role of individual genes, crosstalk between these pathways remains largely
unexplored as a whole. Particularly in the cancers of gluconeogenic cell lineages, there
are few published studies on the effects of glucagon, gluconeogenesis, and glycogen on
glucose metabolism. For example, HIF-driven kidney cancers display greater levels of
glycogen than normal renal epithelium, as do many tumors, but the metabolic purpose or
consequences resulting from that increased tumor glycogen is as of yet, unknown. In
liver cancer which mostly originates from hepatocytes, the dominant gluconeogenic cell
type, it is similarly unknown if deregulated hepatic GCGR activity accounts for some of
the correlations between gluconeogenic gene expression and liver cancer progression.
Furthermore, studies have not addressed if kidney or liver cancer cells are
responsive to glucagon. Research into glucagon and GCGR has predominantly been
focused on diabetes, whereby GCGR antagonists are being tested to therapeutically
control hyperglycemia (Sharma et al, 2018) 155. While inactivating mutations in GCGR
can lead aberrant amino acid signaling and result in a rare type of pancreatic
neuroendocrine tumor (Zhou et al, 2009; Yu et al, 2011)155,157, as mentioned previously,
the literature is very limited with regards to the general role of glucagon signaling in
cancer (Yagi et al, 2018)158. With this in mind, this body of work aims to study the roles
of glucagon, gluconeogenesis, and glycogen in the context of liver and kidney cancer.

1.4 Background on Liver and Kidney Cancer
Liver Cancer
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Primary liver cancer, or hepatocellular carcinoma (HCC), is the 4th most common
tumor type and is estimated to affect over 1 million people worldwide (Villanueva, 2019;
Kim and Viatour, 2020)159,160. HCC also represents the second leading cause of cancer
deaths globally, with mortality rates steadily increasing over the past 20 years (American
Cancer Society, 2018)161. HCC is characterized as a progressive, often inflammatory,
disease with the following risk factors: alcohol abuse, obesity-related non-alcoholic
steatohepatitis, chronic hepatitis C or B infections, aflatoxin exposure, hereditary
hemochromatosis, anabolic steroids, and tobacco use. Many of these pathological
insults mechanistically lead to liver damage and ultimately cirrhosis, which reports
estimate accounts for 80% of all HCC (Simonetti et al, 1991) 162. While surgery remains
the most effective treatment for early, single nodule HCC, current non-surgical treatment
options, such as transarterial chemoembolization and radiofrequency ablation, have
limited efficacy and reflect the poor five-year survival rates of 12%, averaged across all
disease stages (Bedossa and Paradis, 2011)163.
A major obstacle to effective treatment is due in large part to the genetic
heterogeneity of hepatic tumors. For example, unlike melanomas which often harbor
targetable mutations in the oncogene BRAF, HCCs display a diverse set of nondruggable mutations, specifically in the gene, CTNNB1, which encodes β-catenin and is
present in approximately 30% of HCC patients. These driver mutations were found to be
predictive of better overall survival (Wang et al, 2015) 164. Promoter mutations in the gene
encoding for telomerase, TERT, is thought to be a common early event in HCC initiation,
that distinguishes regenerative nodules to neoplastic growths in a background of
cirrhotic liver (Kim et al, 2019; Muller et al, 2020)165,166. Moreover, in HCCs developed
from a non-cirrhotic liver, approximately half of tumors with TERT promoter mutations
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also harbored activating mutations in CTNNB1 (Nault et al, 2013)167. In contrast,
mutually exclusive mutations in the tumor suppressor gene, TP53, account for another
30% of tumors, which generally correlate with enhanced cancer cell aggression and
shorter overall survival (Villanueva and Hoshida, 2011)168.
Patient response to targeted therapy has been disappointing, as Sorafenib, an FDAapproved kinase inhibitor for advanced HCC, only extends survival by a couple of
months (Llovet et al, 2008; Bruix et al, 2015)169,170. Clinical trials incorporating
immunotherapies are ongoing (Pinato et al, 2020) 171, but preliminary data comparing the
efficacy of Nivolumab, targeting the anti-T cell modulator PD1, to Sorafenib has not yet
shown any statistical benefit in median overall survival or progression-free survival as a
monotherapy (NCT02576509). However, a recent phase 3 clinical trial in 501 patients
with inoperable HCC demonstrated that treatment with a related immunotherapeutic,
Atezolizumab, in tandem with an anti-angiogenic agent, Bevacizumab, provided an
additional 2.5 months of median progression-free survival (Finn et al, 2020)172. This
suggests that optimal drug interventions may require combination strategies against
multiple aspects of tumor biology. Nevertheless, these clinical and molecular
observations underscore HCC heterogeneity (Jeng et al, 2015; Ally et al, 2017)173,174 and
the necessity of new treatment strategies.
Targeting tumor metabolism, specifically disrupting glycolysis and promoting
gluconeogenesis, may represent a therapeutic opportunity applicable across liver
cancers. According to The Cancer Genome Atlas (TCGA), normalized RNA-seq reads of
enzymes that directly catalyze gluconeogenesis are robustly decreased across liver
cancer patients. Moreover, the response to glucagon, a master regulator of
gluconeogenic gene expression, has not been evaluated in the context of liver cancer.
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Therefore, a precise investigation into the potential tumor suppressive role of glucagon
signaling in liver cancer was required.
Kidney Cancer
Kidney cancer ranks 8th in yearly incidence rates out of the nearly 200 distinct cancer
classifications in the US (NCI SEER, 2018)175. In fact, clinical data up to 2017 indicates
that kidney cancer incidence had among the greatest percent increase among males
and females for all cancer types in this latest period analyzed, highlighting a need for
deeper comprehension of the disease. Clear cell renal cell carcinoma (ccRCC) is the
predominant disease subtype, accounting for more than 70% of patient cases, with a
majority of tumors harboring loss-of-function mutations in the von Hippel Lindau (VHL)
tumor suppressor (Sanchez et al, 2018)176. pVHL is an E3 ligase component that
recognizes oxygen-dependent hydroxylation sites on hypoxia inducible factors (HIFs) to
negatively regulate HIF protein levels through the ubiquitin-proteosome system. Only
during acute hypoxia is pVHL unable to interact with HIFs and, by extension, are HIF
proteins stabilized to initiate an adaptive response to low oxygen. The vast majority of
ccRCC tumors lack pVHL expression or function and uniquely exhibit chronic HIF-α
stabilization, regardless of tumor oxygenation. As such, these tumors categorically
display transcriptomic profiles driven by either HIF-1α and HIF-2α together (H1H2) or
HIF-2α solely (H2) (Gordan et al, 2008)177. Recent pharmacological advances in the
development of small molecule inhibitors of HIF-2α, such as PT2385, have shown
therapeutic promise in preclinical and clinical settings, supporting oncogenic addiction to
HIFs in ccRCC (Wallace et al, 2016; Courtney et al, 2018)178,179. However, the scope of
HIF-controlled downstream pathways that are clinically relevant for disease progression
remains incompletely defined.
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Perhaps the most striking phenotypic aftermath of pVHL deficiency in ccRCC tumors
is a histologically clear cytoplasm. This is due to the removal of large intracellular lipid
droplets, harboring cholesterol esters and triglycerides, and accumulated granules of
glycogen during tissue processing for pathology (Zhang et al, 2017; Riscal et al,
2019)180,181. We previously reported that HIF-2α promotes lipid storage by regulating the
expression of an essential lipid droplet coat protein, Perilipin-2 (PLIN2), in ccRCC (Qiu et
al, 2015)182. PLIN2 knockdown eradicates lipid droplets and strongly abrogates cell
viability, illuminating the importance of lipid homeostasis in ccRCC (Ackerman et al,
2018)183. However, regulation or biological relevance of glycogen metabolism in ccRCC
has not been investigated in careful detail, despite emerging data that support a protumorigenic role for glycogen in other cancers, such as glioblastoma (GBM) and nonsmall cell lung cancer (NSCLC), under metabolic stress conditions (Favaro et al, 2012;
Sun et al, 2019)184,185. Therefore, a thorough assessment of glycogen metabolism in
ccRCC was warranted.

1.5 Study Rationale, Experimental Hypotheses, and Project Goals
Based on the aforementioned literature data and our current understanding of cancer
metabolism, along with its therapeutic potential, we propose the following project
questions (Fig. 1.3; pg. 32): (1) can glucagon signaling induce gluconeogenic gene
expression to perturb liver cancer growth? The rationale for this investigation lies in the
natural role of gluconeogenesis in directly opposing glycolysis. Since glucose catabolism
is vital for tumor growth, we hypothesized that if glucagon signaling can activate
gluconeogenesis in liver cancer cells, it would have a tumor suppressive effect.
Therefore, the goals of this project are to describe the biological consequences of
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glucagon/GCGR stimulation in liver cancer models, through ELISAs measuring cAMP
production, western blots of downstream effector activity, qPCR assessment of target
gluconeogenic gene expression, and cell viability assays.
(2) Can disruption of glycogen metabolism diminish tumor cell proliferation in kidney
cancer? The rationale for this query originates from the uncharacterized role of elevated
glycogen in kidney cancer, which could theoretically store glucose under hypoxic
conditions for optimal catabolism. However, since the majority of clear cell renal cell
carcinoma are driven by HIFs, regardless of oxygenation, the metabolic balance
between glycogen synthesis and breakdown is unclear, and it may be that simply
perturbing the equilibrium one way or the other results in reduced cancer cell viability.
Thus, the goals of this project are to qualify the effects of blocking either GYS1-mediated
glycogen synthesis or PYGL/B-regulated glycogenolysis by CRISPR/Cas9 technology,
followed by quantification of glycogen levels, in vitro and in vivo proliferation rates, and
metabolic tracing of glycogen-derived glucose during nutrient deprivation.
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Figure 1.1 – Major glucose metabolic pathways. By facilitated diffusion across its concentration gradient, glucose entry
into the cell is initially met with phosphorylation by hexokinase. This glucose-6-phosphate is then processed via multiple
reactions to produce energy, anabolic precursors, and redox homeostasis necessary for cell function and viability. GLUT:
glucose transporter, G6PC: glucose-6-phosphatase catalytic subunit, HK: hexokinase, G6P: glucose-6-phosphate, G6PD:
glucose-6-phosphate dehydrogenase, NAD(P)H: nicotinamide adenine dinucleotide (phosphate), F6P: fructose-6phosphate, GFAT: glucosamine--fructose-6-phosphate aminotransferase, CoA: Coenzyme A, UT(D)P: uridine
tri(di)phosphate, GlcNAc: n-acetylglucosamine, OGT: o-linked GlcNAc transferase, FBP: fructose-1,6-bisphosphatase,
PFK: phosphofructokinase, F-1,6-BP: fructose-1,6-bisphosphate, GPD: glycerol-3-phosphate dehydrogenase, GPAT:
glycerol-3-phosphate acyltransferase, PHGDH: 3-phosphoglycerate dehydrogenase, (me-)THF: (methyl-)tetrahydrofolate,
PEP: phosphoenolpyruvate, PK: pyruvate kinase, MPC: mitochondrial pyruvate carrier, PDC: pyruvate dehydrogenase
complex, PC: pyruvate carboxylase, OAA: oxaloacetate, ACC: acetyl-CoA carboxylase, AT(D)P: adenosine
tri(di)phosphate.
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Figure 1.2 – Glucagon signaling. Glucagon binds its specific receptor to stimulate heterotrimeric G-protein signaling that
produces cAMP and cytosolic Ca+2. Signal transduction is further mediated by PKA and CAMKII to promote
glycogenolysis, lipolysis and fatty acid oxidation, and lastly gluconeogenesis. GCGR: g-coupled glucagon receptor,
G(s/q)//: guanine nucleotide-binding protein alpha(s/q)/beta/gamma subunits, GT(D)P: guanosine tri(di)phosphate, AC:
adenylyl cyclase, cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, PIP2: phosphatidylinositol-4,5bisphosphate, IP3: inositol triphosphate, IP3R: inositol triphosphate receptor, HSL: hormone-sensitive lipase, PYG:
glycogen phosphorylase, CAMKII: Ca+2/calmodulin-dependent protein kinase II, AMPK: AMP-activated protein kinase,
ACC1: acetyl-CoA carboxylase 1, ATGL: adipose triglyceride lipase, FOXO1: forkhead box O1, CREB: cAMP-response
element-binding protein, CBP: CREB-binding protein, PGC1: peroxisome proliferator-activated receptor gamma
coactivator 1 alpha.
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Figure 1.3 – Determining the roles of glucagon in liver cancer & glycogen in kidney cancer. For Chapter 2, our goal
is to determine the effects of glucagon signaling in liver cancer. To that end, the glucagon receptor GCGR will be
overexpressed in liver cancer cell models, followed by a pathway specific evaluation of signaling and gluconeogenic gene
transcription. For Chapter 3, our aim is to characterize the function of elevated glycogen in kidney cancer. To accomplish
this, both glycogen synthesis and breakdown will be disrupted via genetic and/or small molecule inhibition, followed by cell
viability assessment. Additionally, glycogen-derived glucose tracing will be performed to elucidate how glycogen is utilized
under nutrient-deprived conditions.
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CHAPTER 2: Glucagon Signaling via Supraphysiologic GCGR can Reduce Cell
Viability without Stimulating Gluconeogenic Gene Expression in the Liver Cancer
Cells

Portions of this chapter have been adapted from:
(1) Godfrey J, Skuli N, Riscal R, and Simon MC. Glucagon signaling via
supraphysiologic GCGR reduces cell viability without stimulating gluconeogenic
gene expression in the liver cancer cell line, SNU398. Manuscript in preparation.
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2.1 Abstract
Downstream biochemical processing of glucose in tumor cells, such as aerobic
glycolysis, provides energy, anabolic precursors, reducing power, and other metabolites
necessary for mitogenic engagement and environmental adaptability, creating an
attractive therapeutic target. Here, we test the hypothesis of whether glucagon signaling
can antagonize glycolysis by activating gluconeogenesis to reduce tumor proliferation in
models of liver cancer. Liver cancer cell lines were infected with a lentiviral construct
driving constitutive expression of the g-coupled glucagon receptor, GCGR. ELISA
assays show an increase in cAMP abundance specifically in liver cancer cell lines
overexpressing GCGR treated with 100nM glucagon. Western blot analysis of a
glucagon-responsive transcription factor downstream of cAMP/PKA, CREB, reveal
greater levels of activated S133 phosphorylation localized to the nucleus in SNU398
GCGR cells. However, qPCR data indicate that none of the three major gluconeogenic
genes: G6PC, FBP1, or PCK1, are elevated at the mRNA level in SNU398 GCGR cells
when treated with glucagon. Moreover, their expression cannot be fully restored to levels
measured in primary human hepatocytes even in the presence of multiple epigenetic
inhibitors. Regardless, glucagon-treated SNU398 GCGR cells showed a reproducible,
two-fold increase in PI/Annexin V staining that was further validated by proliferation
assays measuring 50% or more reduction in SNU398 GCGR cell number when exposed
to glucagon. Rescue experiments utilizing siRNA or pharmacological inhibition of CREB
showed no increase in SNU398 GCGR cell number in the glucagon condition,
suggesting a CREB-independent, tumor suppressive function of glucagon signaling in
SNU398. Overall, our work describes a novel finding that restrained cell viability of a liver
cancer model can be actualized through glucagon signaling.
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2.2 Materials and Methods
Cell Lines and Culture
The following liver cancer cell lines were purchased from the American Type Culture
Collection (ATCC): SNU182 (hepatocellular carcinoma, P53S215I/S215I, catalog # CRL2235), SNU387 (hepatocellular carcinoma, NRAS Q61K/+, P53K164*/K164*, catalog # CRL2237), SNU398 (hepatocellular carcinoma, -cateninS37C/+, catalog # CRL-2233), SNU423
(hepatocellular carcinoma, P53 splice site mutation, catalog # CRL-2238), SNU449
(hepatocellular carcinoma, P53 A161T/A161T, catalog # CRL-2234), SNU475 (hepatocellular
carcinoma, P53N239D,G262D/+, catalog # CRL-2236), HepG2 (hepatoblastoma, NRASQ61L/+,
catalog # HB-8065), Hep3B (hepatocellular carcinoma, Axin1 R146*/R146*, catalog # HB8064), PLC (hepatoma, P53 R249S/R249S, catalog # CRL-8024), and SKHEP1 (hepatocellular
carcinoma, BRAFV600E/+, catalog # HTB-52). Huh7 (hepatoma, P53 Y220C/Y220C) was a gift
from Dr. Terence Gade. The patient-derived xenograft cell line, M7571, was a gift from
Drs. Terence Gade and Katy Wellen. Top oncogene hotspot mutations listed for each cell
line were compiled from the Broad Institute Cancer Cell Line Encyclopedia
(https://portals.broadinstitute.org/ccle). 293T cells were purchased from the ATCC
(catalog # CRL-3216). All cancer cell lines were maintained in RPMI 1640 medium (Gibco,
catalog # 21875034) with 10% fetal bovine serum (Gemini Bio, catalog # 900-108), 1%
penicillin/streptomycin (Gibco, catalog # 15140122), and incubated at 21% oxygen/5%
carbon dioxide. These cells were passaged by aspirating media, washing with DPBS
(Corning, catalog # 21-031-CM), detached from plates with 0.25% trypsin-EDTA (Gibco,
catalog # 25200056), and re-plated with fresh 10% FBS-containing RPMI media. Most
experiments were performed at 5% FBS. For glucose dependent growth assays, cells
were cultured in RPMI medium without glucose (Gibco, catalog # 11879020) with dialyzed
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FBS (Gemini Bio, catalog # 100-108). For lipid dependent growth assays, cells were
cultured with delipidated FBS (Gemini Bio, catalog # 900-123). Primary human
hepatocytes (PHH) obtained from Life Technologies (catalog # HMCS15) and directly
lysed for RNA and protein analysis only without prior culturing. Cryoplateable primary
human hepatocytes (cPHH) were obtained from Sigma-Aldrich (discontinued, catalog #
MTOXH1000), thawed in Human Hepatocyte Thawing Medium from Sigma-Aldrich,
(discontinued, catalog # MED-HHTM), and cultured in Human Hepatocyte Culture Medium
from Sigma-Aldrich (discontinued, catalog # MED-HHCM) on collagen-coated plates.
THLE3 cells (ATCC, catalog # CRL-11233) were seeded on plates coated overnight with
0.03mg/ml bovine collagen type I (Life Technologies, catalog #A1064401), 0.01mg/ml
bovine fibronectin (Sigma-Aldrich, catalog # F1141), and 0.01mg/ml BSA (Sigma-Aldrich,
catalog # A9576) in modified BEGM medium (Lonza, catalog # CC-3171) without
gentamycin, amphotericin, or epinephrine and with an extra 5ng/ml EGF (Corning, catalog
# CB-40052), 70ng/ul p-ethanolamine, 1% PenStrep, and 10% FBS.
Compounds
Hormones and inhibitors used in culture for in vitro experiments were as follows:
Glucagon (Sigma-Aldrich, catalog #) was prepared in 0.05M acetic acid (Sigma-Aldrich,
catalog # 6283) at a concentration of 1mg/ml. Forskolin (MedChem Express, catalog #
HY-15371) was prepared in DMSO (Sigma-Aldrich, catalog # 2650) at a stock
concentration of 10mM. 666-15 (Sigma-Aldrich, catalog # 5383410001) was prepared in
DMSO at a stock concentration of 10mM. Palbociclib (Selleck Chemicals, catalog #
S1116) was prepared in DMSO at a stock concentration of 10mM. GSK126 (Selleck
Chemicals, catalog # S7061) was prepared in DMSO at a stock concentration of 10mM.
LBH589 (Selleck Chemicals, catalog # S1030) was prepared in DMSO at an initial
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concentration of 10mM and diluted to 0.1mM for a working stock solution. Decitabine
(Selleck Chemicals, catalog # S1200) was prepared in DMSO at a stock concentration of
10mM. Sorafenib (Selleck Chemicals, catalog # S1040) was prepared in DMSO at a
stock concentration of 10mM. UNC0642 (Selleck Chemicals, catalog # S7230) was
prepared in ethanol (Decon labs) at a stock concentration of 10mM.
Plasmid purification and cloning
Bacterial cultures of pLenti-CMV-eGFP-PURO (Addgene, catalog # 17448) and
pCR4-TOPO-GCGR (Dharmacon, catalog # MHS6278-202857850) were grown in 1X
LB (Difco) plus Carbenicillin (Sigma-Aldrich, catalog # c1389) overnight at 30 degrees
Celsius with shaking. DNA plasmid minipreps were performed according to the kit
manufacturer (Qiagen, catalog # 27106). GCGR cDNA was PCR-amplified to include
XbaI and SalI restriction enzyme sites with the forward primer (5’GATACTTCTAGAATGCCCCCCTGCCAGCC-3’) and reverse primer (5’GATACTGTCGACTCAGAAGGGGCTCTCAGCCA-3’), respectively. GCGR cDNA and
pLent-CMV-eGFP plasmid were digested with XbaI and SalI, and purified following
agarose gel electrophoresis with QIAquick gel extraction kit (catalog # 28706). Purified,
digested GCGR cDNA and pLenti-CMV vector backbone were then ligated and used to
transform TOP10 (OneShot) cells. Colonies with successful ligations were picked and
re-streaked on LB-Carbenicillin plates overnight at 30 degrees Celsius. New minipreps
were made on a few colonies and validated by Sanger sequencing with the CMV forward
primer (CGCAAATGGGCGGTAGGCGTG) at the Children’s Hospital of Philadelphia
Sequencing Core Facility.
Lentiviral Infection and siRNA Transfection
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To generate lentivirus for stable integration and expression of eGFP or GCGR,
approximately 400,000 293T cells were seeded in 6-well plates without PenStrep. The
following day, cells were transfected with 3 plasmids prepared in OPTI-MEM (Gibco,
catalog # 31985070): 3g of pLenti-eGFP or pLenti-GCGR, 3g of psPAX2, and 0.3g
of pMDG.2 with 3l FuGENE reagent (Promega, catalog # E2691) per well. The next
day, media was aspirated and fresh 10-30% FBS-containing media was added to each
well for 24-48hr incubation. Virus was harvested by filtering media through a 0.45m
filter (Millex-HV). Viral solutions were aliquoted into cryovials and stored in -80 degrees
Celsius and all supplies in contact with virus were bleached. Liver cancer cells were
infected with 250-1000l of virus in 1.5ml total media, containing 8g/ml polybrene
(Sigma-Aldrich, catalog # 107689). After 24-48hrs, stably expressing eGFP- or GCGRcells were selected by puromycin (Sigma-Aldrich, catalog # P9620) at a concentration
range between 1-5g/ml. For siRNA transfections, pooled siRNAs were purchased from
Dharmacon to target CREB1 (catalog # L-003619-00-0005) and controls, Cyclophilin B
(catalog # D-001820-10-20) or a non-targeting sequence (catalog # D-001810-10-05).
Transfections were performed according to the manufacturer’s recommendation.
SNU398 cells were seeded in 6-well plates at approximately 30-40% confluency (50,000
- 100,000 cells) and at the indicated time point were transfected with 25nM of siRNA in
OPTI-MEM with 2-6l lipofectamine (Fisher Scientific, catalog # 13778030) per well. The
next day, media was aspirated and cells were given the appropriate, fresh media.
Proliferation (cell # or density) Assays
Cells were seeded in 6-well or 12-well plates at approximately 30-40% confluency
(50,000 - 100,000 cells for 6-well and 25,000 - 50,000 cells for 12-well) in 10% FBS38

containing RPMI. The following day, media was aspirated and the experimental conditions
were added, with this process repeated over the duration of the experiment, as described
in each figure. For cell number quantifications, at the indicated time points, media were
aspirated, washed with DPBS, trypsinized with 0.5ml (6-well) or 0.25ml (12-well), and then
neutralized with equivalent volumes of 10% FBS-containing media. Next, 10l of cells was
mixed with 10l of 0.4% Trypan Blue (Gibco, catalog # 15250061) and finally counted in
a Countess II (Life Technologies), with live cell/ml concentrations corrected for a 1:1
dilution. Quantifications were further analyzed in Microsoft Excel and Prism 9. For crystal
violet colorimetric assays, at the indicated time points, media were aspirated and then 1ml
(6-well) or 0.5ml (12-well) of 0.5% crystal violet (Sigma-Aldrich, catalog # C6158)/20%
methanol (Sigma-Aldrich, catalog # 179337) solution in ddH 2O was added down the sides
of each well. Cells were incubated with crystal violet for 10 minutes with gentle rocking.
Crystal violet solutions were aspirated and then cells were washed twice with DPBS. For
the last wash, cells were gently rocked in DPBS for at least an hour to help remove
background staining. Following DPBS aspiration, plates were inverted and dried overnight.
Images were taken by a scanner (Epson Perfection 4490 Photo, discontinued) and
assembled into figure format in Adobe Photoshop 2020. Quantification of crystal violet
staining was performed by adding an equivalent volume of 99.8% methanol, incubating
plates at room temperature for at least 1 hour, and then reading absorbance at OD 570nm
(Feoktistova et al, 2016)186.
Viability (ATP-based) Assays
Cells were seeded in white, opaque, flat bottom 96-well plates (Corning, catalog #
CLS3917) at approximately 30-40% confluency (1000 - 4000 cells) in 50l of 10% FBScontaining RPMI. The following day (Day 0), 50l of experimental media conditions at a
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2X concentration were added to the appropriate wells and incubated for the indicated
durations. At Day 0, 50l of normal media was added to a separate plate for a baseline
reading. For all readings, 50l of Cell Titer Glo reagent (Promega, catalog # G9242) was
added directly to each well and incubated at room temperature while shaking for 10
minutes. Luminescence was measured by a microplate reader (SpectraMax M2,
Molecular Devices) with the settings at white/opaque plate, top read, and 3 reads per
sample rate. Further numerical analysis, such as normalization to baseline, were
calculated with Microsoft Excel and Prism 9.
Apoptosis (propidium iodide & annexin v-based) Flow Cytometry
Cells were seeded in 6-well plates at approximately 30-50% confluency (50,000 200,000 cells) in 10% FBS-containing RPMI. The following day, media was aspirated
and the experimental conditions were added, with this process repeated over the
duration of the experiment, as described in each figure. At the endpoint, media was
collected in 15ml conical tubes, cells were washed with DPBS, which was then collected
in the same tubes, and then 0.5ml of trypsin was added to each well. Upon detachment,
cells were transferred into their respective tubes and pelleted by centrifugation at
2000rpm for 5min. Supernatants were discarded and rims of tubes dried by kimwipe.
Cell pellets were resuspended in 110l of staining solution containing 5% Annexin V, 5%
Propidium Iodide, and 90% 1X binding buffer (BD Bioscence, catalo # 556547). Next,
cells were filtered through a 35m strainer cap in FACS-compatible tubes (MTC Bio,
catalog # T9005) and incubated in the dark for 15 minutes at room temperature. 300l of
1X binding buffer was added, vortexed, and then flow analysis was performed with a BD
FACSCalibur. Stained cells were kept on ice and protected from light when not being
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processed. Gates were drawn to obtain data for at least 10,000 single cell events.
FlowJo software was used to further process data.
Gene Expression Analysis
For patient data, mRNA expression was obtained from The Cancer Genome Atlas
(TCGA) (https://www.cbioportal.org). Raw RNA-seq reads were normalized and
presented as log2 values by Dr. John Tobias (University of Pennsylvania). These
calculations were graphed and statistically analyzed using Prism 9. Kaplan-Meier
probability curves for overall survival comparing expression of a given gene was
obtained from the website tool, https://kmplot.com (Nagy et al, 2021)187. Briefly, a TCGA
RNA-seq dataset for liver cancer with 364 patient tumor samples was assessed for most
statistically significant correlation between high vs. low gene expression and the
probability of patient survival. For experimental studies in general, cells were seeded in
6-well plates in 10% FBS-containing RPMI at approximately 30-50% confluency (50,000
- 200,000 cells) for <24hr durations or at 50-70% confluency (200,000-400,000 cells) for
>24hr time points. At the designated endpoint, media was aspirated, cells were washed
with 1ml of 1X DPBS on ice, aspirated again, and then RNA extraction was performed
with the Qiagen RNeasy kit (Qiagen, catalog # 74104), following the manufacturer’s
protocol. RNA concentrations were determined using a NanoDrop 1000 (Thermo Fisher
Scientific). Next, between 0.25-1g of RNA was reverse transcribed into cDNA with the
High-Capacity RNA-to-cDNA kit (Applied Biosystems, catalog # 4388950). A ratio of 10l
buffer and 1l enzyme per 20l total volume was used. Reactions were prepared in strip
tubes (Thermo Fisher Scientific, catalog # AB-0773) and a RT-PCR cycle program was
run in a C1000 Thermal Cycler (BioRad) with reaction settings of 37/36:00, 95/3:00.
cDNA samples were diluted in ddH2O by 10-20-fold depending on the amount of RNA
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used. qPCR of target genes was performed in a ViiA7 using 5.4l of cDNA with 0.6l
TaqMan primers (Thermo Fisher Scientific) per reaction and 6.6l (6ul buffer, 0.6ul
enzyme) of TaqMan Fast Advanced Master mix (Life Technologies, catalog # 4444965).
All qPCR reactions were performed in three technical triplicates. Raw Ct values were
converted into Ct by first subtracting the technical replicate average of the
housekeeping gene (RNA45S) from the Ct value of each target gene (=Ct). Then Ct
values were converted to expression with the formula =2^-Ct. Expression values were
then normalized to the triplicate average of the vehicle or primary human hepatocyte
sample (=Ct). Taqman primers used for this work are the following: housekeeping
gene RNA45SR (catalog # Hs03928985_g1), GCGR (catalog # Hs00164710_m1),
G6PC (catalog # Hs02560787_s1), FBP1 (Hs00983323_m1), PCK1 (catalog #
Hs00159918_m1).
Protein Analysis
For experimental studies in general, cells were seeded in 6-well plates in 10% FBScontaining RPMI at approximately 30-50% confluency (50,000 - 200,000 cells) for <24hr
durations or at 50-70% confluency (200,000-400,000 cells) for >24hr time points. At the
designated endpoint, media was aspirated, cells were washed with 1ml of 1X DPBS on
ice, aspirated again, and then 50-200l of whole cell extract lysis buffer (3% of 5M NaCl,
1% of 1M Tris pH 7.6, 0.1% SDS, 1% of 0.5M EDTA, and 1X protease/phosphatase
inhibitor cocktail (Thermo Fisher Scientific, catalog # 78444) in ddH 2O) was added to
each well and incubated on ice for at least 10min. Cells were scraped and transferred
into a 1.5ml microfuge tube. Following 10s sonication pulses per tube, samples were
spun down at 13,000 RPM for 10min in 4 degrees Celsius. Protein supernatants were
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pipetted into new 1.5ml microfuge tubes. For subcellular fractionation, nuclear and
cytosolic protein samples were extracted using the NE PER kit (Thermo Fisher
Scientific, catalog # 78833), following the manufacturer’s protocol. Sample
concentrations were performed by BCA (Pierce), following the manufacturer’s protocol,
and calculated in Microsoft Excel using trendline analysis comparing the OD 562nm of
samples to a standard curve of BSA. For western blots, depending on the concentration,
between 5-40g of protein (in 1X sample buffer, 1% beta-mercaptoethanol (SigmaAldrich, catalog # M3148)) were loaded into SDS-acrylamide PAGE gels (4% stacking,
10-12% running) and ran at 100-130V for 60-90 minutes. Proteins were then transferred
onto nitrocellulose membranes in a transfer apparatus at 0.1A overnight in 4 degrees
Celsius. Membranes were blocked with 5% nonfat milk in 1X TBST for approximately 1hr
at room temperature. Following a few washes with 1X TBST, membranes were cut with
scissors at the appropriate sizes and incubated with the corresponding primary
antibodies (prepared in 1X TBST, 5% BSA, 0.01% sodium azide) overnight at 4 degrees
Celsius with rocking. The following day, antibody solutions were pipetted into original
tubes for future use, membranes washed 2-3 times with 1X TBST, and then incubated
with 1:10,000 secondary antibody conjugated to HRP for 1hr at room temperature with
rocking. Antibody solutions were discarded and membranes were washed 3 times with
1X TBST over the course of an hour. Autoradiography film processing of membranes
were performed in a dark room. Films were scanned and protein band images were
cropped for figure production by Adobe Photoshop. Primary antibodies used for this
work are the following: -Actin (Cell Signaling Technology, catalog # 3700), GAPDH
(Cell Signaling Technology, catalog # 2118), GCGR (Invitrogen, catalog # PA5-50668),
eGFP (Thermo Fisher Scientific, catalog # CAB4211), p-PKA substrates (Cell Signaling
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Technology, catalog # 9624S), p-CREB S133 (Cell Signaling Technology, catalog #
9198), total CREB (Cell Signaling Technology, catalog # 9197), H3K27me3 (Cell
Signaling Technology, catalog # 9733), H3K27Ac (Cell Signaling Technology, catalog #
8173), total H3 (Cell Signaling Technology, catalog # 14269), DNMT1 (Cell Signaling
Technology, catalog # 5032), cleaved PARP (Cell Signaling Technology, catalog #
5625), cleaved Caspase-3 (Cell Signaling Technology, catalog # 9664), Cyclophilin B
(Abcam, catalog # ab16045), p-CaMKII T286 (Cell Signaling Technology, catalog #
12716).
ELISA Assays
For cAMP quantification, cells were seeded in 6-well plates in 10% FBS-containing
RPMI at approximately 30-50% confluency (50,000 - 200,000 cells) for <24hr durations
or at 50-70% confluency (200,000-400,000 cells) for >24hr time points. At the
designated endpoint, media was aspirated, cells were washed with 1ml of 1X DPBS on
ice, aspirated again, and then 200l of 1N HCl was added to each well for lysis. The
remaining steps were carried out according to the manufacturer’s protocol (Enzo Life
Sciences, catalog # ADI-900-066). For serum glucagon quantification, blood was initially
collected by retroorbital draw and allowed to clot at room temperature for one hour.
Samples were then centrifuged at 3000RPM for 10min in 4 degrees Celsius and serum
supernatant was transferred into a new 1.5ml microfuge tube. From here, quantification
of glucagon was determined by following the manufacturer’s protocol (R&D Systems,
catalog # DGCG0). Sigmoidal regression analysis and extrapolations were calculated in
Prism for final concentrations.
Mouse Experiments
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All experiments described were approved by IACUC at the University of
Pennsylvania. All mice used for xenograft experiments were 4-6 weeks old Nu/J females
(Jackson Laboratory, catalog # 002019). Following a few days of acclimation, mice were
anesthetized with isofluorane and 1-2 million SNU398 liver cancer cells (in a 1:1 mixture
of DPBS:matrigel) were subcutaneously injected into both flanks. After approximately 23 weeks, xenograft tumors reached an average of 100mm3, caliper measured, at which
point experimental treatments began. The EZH2 inhibitor, GSK126, and pan-HDAC
inhibitor, LBH589, were prepared at the indicated concentration in 20% 2-hydroxypropyl-cyclodextrin (Cayman Chemical, catalog # 16169) pH 4.5 either as a single agent or in
combination. 200l of the drug solutions was intraperitoneally injected once daily unless
mice displayed toxicity symptoms, such as severe weight loss and lethargy, at which
point drugs were administered irregularly following weight recovery. Once tumors
reached 2000mm3, mice were euthanized by CO2, followed by cervical dislocation.
Tumors were resected and frozen on dry ice for further processing. Tumor volumes were
calculated by the following equation: (/6) x (width2) x (length), where width is always the
shorter parameter.

2.3 Results
Gluconeogenic Proteins are Downregulated in Glucose-Dependent Liver Cancer Models
To provide a rationale for targeting glucose metabolism via glucagon-stimulating
gluconeogenesis in liver cancer, we probed the necessity of glucose for cell viability. Cells
that require more glucose may exhibit increased vulnerability to agents stimulating
gluconeogenesis, such as glucagon. To that end, 11 established cell line models of liver
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cancer, with various disease etiology and oncogenic driver mutations (see Table 2.1; pgs.
68 and 69), were cultured in vitro under glucose-limiting conditions and cell numbers were
quantified after approximately one week of growth. All cell lines tested were unable to
proliferate in 0mM glucose conditions, and in particular, SNU398, SNU182, and SNU475
cells were unable to fully recover even in physiological 5mM glucose concentrations (Fig.
2.1A, and Supp. Fig. 2.1A; pgs. 60 and 61).
Previous studies have demonstrated the key role of hepatic lipolysis, via the activation
of inositol triphosphate receptor 1 and adipose triglyceride lipase, in glucagon-stimulated
gluconeogenesis (Perry et al, 2020) 120. Moreover, the metabolic effects of glucagon
contribute to hepatic fat clearance in fatty liver disease models (Finan et al, 2016) 188,
suggesting glucagon-induced depletion of lipid stores may reduce viability in liver cancer
cells that demand more fatty acids for growth. To examine lipid dependency, we compared
endpoint proliferation between cells cultured with normal serum, delipidated serum, or
delipidated serum with oleic acid supplementation. Unlike glucose, more varied results
were obtained across cell lines (Fig. 2.1A, and Supp. Fig. 2.1B; pgs. 60 and 61). This
lipid phenotypic distribution did not appear to be due to relative growth rate or oncogenic
driver (data not shown), which may simply indicate that not all cell lines are able to perform
adequate de novo lipogenesis under nutrient deprivation. Short-term cell viability
assessment of growth recapitulated these findings across all cell lines tested, reinforcing
the conclusion that all liver cancer cells require glucose but not lipids (Supp. Fig. 2.1C, D;
pg. 61). At the very least, this highlights a critical role of glucose in the growth of
established liver cancer cells, which is not ubiquitously observed in all cancers, like soft
tissue sarcomas (Lee et al, 2020)88.
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The inability of liver cancer cells to proliferate under 0mM glucose supports the
hypothesis

that

any

process

that

antagonizes

glucose

utilization,

such

as

gluconeogenesis, may suppress tumor growth. Gluconeogenesis is the direct biochemical
reversal of glycolysis, whereby three rate-limiting enzymes, PCK1, FBP1, and G6PC, work
to synthesize glucose and ultimately release it from the hepatocyte (Supp. Fig. 2.1E; pg.
61). In both liver cancer cell lines and patients, all major gluconeogenic genes are
significantly downregulated in tumors compared to normal liver tissue (Supp. Fig. 2.1F,
G; pg. 61). In contrast, this expression pattern was not observed across all glycolytic
genes (data not shown), suggesting that gluconeogenic dampening may be more vital
than direct glycolytic acceleration in liver cancer development. We hypothesized that
silencing across all gluconeogenic genes involved a deficient upstream node of the
pathway.
Physiologically, hepatocytes initiate production of glucose upon prolonged glucagon
signaling via its receptor, GCGR, which stimulates a cascade of signaling events mediated
by cAMP and PKA that activate transcription factors, such as CREB, to induce
gluconeogenic and lipolytic gene expression (Fig 2.1B; pg. 60). Similar to the
gluconeogenic enzymes, GCGR is also significantly downregulated at the mRNA level in
both liver cancer patient samples and cell lines (Fig. 2.1C, D; pg. 60). Whereas normally,
GCGR is most abundant in the liver versus any other tissue type, we also detected a
comparable decrease in GCGR expression in the immortalized, normal hepatocyte cell
line, THLE-3 (data not shown). This data suggests that either artefactual contributions
from 2D growth or early mutagenic events inhibiting tumor suppressor genes may account
for GCGR repression in liver cancer. Regardless, based on RNA-seq data analyzed by
the website tool, https://kmplot.com (see Methods), tumors with lower gene expression of
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GCGR and the gluconeogenic enzymes correlate with shorter overall survival in liver
cancer patients (Fig. 2.1E and Supp. Fig. 2.1H, respectively; pgs. 60 and 61).
Overexpression of GCGR Activates Glucagon-Mediated Signaling Transduction via
cAMP in SNU398 Cells
Based on strict glucose requirements for cell growth, a ubiquitous decrease in GCGR
mRNA in liver cancer samples, and the positive correlation between GCGR expression
and patient survival, we hypothesized that glucagon signaling downstream of GCGR may
restore gluconeogenic expression and drive anti-tumorigenic effects. To examine this
possibility, GCGR cDNA was overexpressed in the human hepatocellular carcinoma cell
line SNU398, which notably harbors a constitutively active mutation in -catenin. RNA and
protein analysis verified the supraphysiologic overexpression of GCGR in SNU398 cells
(Fig. 2.2A, B; pg. 62). To determine whether ectopic overexpression of GCGR can
effectively promote adenylyl cyclase activity in response to glucagon, control (eGFPexpressing) or GCGR-overexpressing cells (referred to as SNU398 GCGR cells) were
treated with glucagon and assayed for cAMP. SNU398 GCGR cells reproducibly
generated cAMP in response to glucagon exposure, which in some cases was as high as
the positive control condition, forksolin, an agonist of adenylyl cyclase (Fig. 2.2C, Supp.
Fig. 2.2A; pgs. 62 and 63), thus confirming that glucagon/GCGR signaling was functional
in this system.
To further investigate glucagon signaling, cAMP-dependent PKA activity was
assessed by phosphorylation of PKA-substrates. SNU398 GCGR cells stimulated with
glucagon showed rapid increases in phosphorylation of PKA targets, including p-CREB
S133 (Fig. 2.2D; pg. 62). Because G-coupled protein receptors can also activate
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phospholipase C and the subsequent release of calcium ions from the endoplasmic
reticulum, we probed for a common effector of glucagon and Ca+2 signaling, CAMKII, but
did not observe any difference in any of its activated isoforms (Fig. 2.2D; pg. 62).
However, we further validated the phosphorylation of CREB by GCGR stimulation over a
longer period of time and range of glucagon concentrations. Phosphorylation of CREB at
S133 was maximally measured with 100nM glucagon, specifically in SNU398 GCGR cells,
with no change in total CREB (Supp. Fig. 2.2B; pg. 63). Although there are other posttranslational modifications reported for CREB, the phospho-S133 site is thought to
enhance the recruitment of necessary transcriptional co-activators (Johannessen et al,
2004)189. Since previous studies in cancer models have demonstrated instances of
mitochondrial CREB localization (Steven et al, 2016) 190, we performed nuclear
fractionations on SNU398 eGFP or GCGR cells treated with glucagon to verify if activated
p-CREB S133 was spatially capable of facilitating gluconeogenic gene transcription. The
glucagon/GCGR-dependent increase in p-CREB was detected in the nuclear fraction (Fig.
2.2E; pg. 62), suggesting that the canonical cAMP-PKA-CREB pathway downstream of
glucagon signaling was functionally intact in SNU398 GCGR cells.
With increased activated CREB in the nucleus, we next quantified the relative mRNA
abundance of G6PC, FBP1, and PCK1, the transcriptional output of glucagon-mediated
gluconeogenesis. Upon glucagon treatment of SNU398 GCGR cells for either 3 or 5 days,
G6PC mRNA levels did not significantly increase relative to control cells (Fig. 2.2F, Supp
Fig. 2.2C; pgs. 62 and 63). Moreover, both FBP1 and PCK1 mRNA expression was
undetected, regardless of condition (data not shown). These data imply that glucagon
signaling in SNU398 GCGR cells, was unable to transmit completely to gluconeogenic
gene transcription. Other cell line models employing this GCGR overexpression strategy
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were similarly examined, and whereas we did measure comparable GCGR expression
(Supp. Fig. 2.2D; pg. 63) and elevated cAMP concentrations upon glucagon treatment
(Supp. Fig. 2.2E; pg. 63), PKA activity and p-CREB were not discernably increased
compared to SNU398 (Supp. Fig. 2.2F; pg. 63).
In contrast to SNU398 GCGR cells, primary human hepatocytes treated with
glucagon displayed trends (1.5-3-fold) towards an increase in gluconeogenic gene
expression for all 3 enzymes, alongside a drop in GCGR mRNA abundance (Supp. Fig.
2.2G; pg. 63). However, it is unclear if this level of change accurately reflects the
physiological response to glucagon in humans, as studies in zebrafish, rat, and murine
hepatocytes have measured increases in PCK1 mRNA anywhere from 4-to-20-to-500fold upon glucagon treatment, respectively (Karanth et al, 2018; Zhang et al, 2011;
Taddeo et al, 2017)191-193. Of note, we did not observe a decrease in GCGR expression
with glucagon treatment in SNU398 or other liver cancer cell lines, but rather a
consistent increase (data not shown). We hypothesize this could be due to increased
levels of the transcription factor, carbohydrate-responsive element binding protein
(ChREBP), in liver cancer (Ribback et al, 2018) 194 that has been shown to positively
regulate GCGR expression in rat hepatocytes (Iizuka et al, 2012)195. Collectively, our
data indicate that glucagon cannot induce a uniform augmentation in gluconeogenic
gene expression in liver cancer cell lines and that SNU398 cells are most responsive to
glucagon upon GCGR overexpression, in terms of downstream signaling.
Co-Treatment of SNU398 GCGR Cells with Glucagon and Epigenetic Inhibitors Cannot
Fully Restore Gluconeogenesis
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Our data shows a signaling cascade from extracellular glucagon to nuclear CREB in
SNU398 GCGR cells, yet this fails to effectively induce gluconeogenic gene transcription,
which we hypothesized would antagonize glycolysis to reduce tumor growth. One
approach to promote transcriptional activation is through inhibiting heterochromatic
epigenetic modifications. Previous studies on the FBP1 loci have indicated that the
presence of biochemical alterations to histones and DNA functionally correlate with
heterochromatin formation and gene silencing. Specifically, promoter-rich methylated
cytosine residues (Chen et al, 2011)196, non-acetylated histone 3 lysine 27 in enhancer
regions (Yang et al, 2017)197, and the chromatin interaction of the histone
methyltransferase, EZH2 (Liao et al, 2020)198, have all been identified as mechanisms of
epigenetic repression for FBP1 in liver cancer. Therefore, we hypothesized that
glucagon/GCGR signaling requires chromatin accessibility in order to fully activate
gluconeogenic gene expression and the accompanying metabolic program.
To that end, we tested the efficacy of 3 epigenetic inhibitors targeting either EZH2specific histone methylation (GSK126), HDAC-mediated histone deacetylation (LBH589),
or DNMT-catalyzed cytosine methylation (Decitabine) (Fig. 2.3A; pg. 64). For GSK126,
reduced EZH2 catalytic activity has been shown to reduce the trimethylation of lysine 27
in histone 3 (H3K27me3) (McCabe et al, 2012) 199. For LBH589, pan-HDAC inhibition
results in broad increases in histone acetylation (Scuto et al, 2008)200. And lastly, for
Decitabine, it has been shown that reduction of DNA methylation is at least partially
through the degradation of DNMTs (Ghoshal et al, 2005)201. As determined by western
blot probing of these specific effects, all 3 compounds were found to be effective in
SNU398 (Fig. 2.3B; pg. 64). To further confirm their efficacy, we treated SNU398 and

51

other cell lines at ranges of drug concentrations for different durations and found similar
effectiveness on their respective target enzymes (data not shown).
Since previous studies have performed experiments assessing gluconeogenic gene
expression following treatment with the above epigenetic drugs as single agents in liver
cancer models, we first tested whether combinations of epigenetic inhibitors themselves
could restore gluconeogenic gene expression to any meaningful degree. After 24hr of drug
treatment, we measured approximately 20-fold increases in expression of FBP1 and
PCK1 with the triple combination in SNU398, while G6PC mRNA level was largely
unchanged across all drug permutations (Fig. 2.3C; pg. 64). Next, we tested whether
GCGR-overexpressing SNU398 cells stimulated with glucagon would be more amenable
to gluconeogenic gene expression with the epigenetic inhibitors. Interestingly, we
observed a different effect on mRNA levels for each gluconeogenic enzyme: (1) G6PC
expression, again, remained unchanged regardless of glucagon/GCGR signaling or
epigenetic inhibition, (2) FBP1 abundance was more dependent on epigenetic regulation
than glucagon/GCGR stimulation, and (3) PCK1 mRNA levels were substantially elevated
only when both glucagon/GCGR signaling and epigenetic inhibition were present (Fig.
2.3D; pg. 64). Importantly, the relative 200-fold increase in PCK1 expression with the triple
combination plus glucagon/GCGR is still at least an order of magnitude less than the PCK1
levels in normal hepatocytes (data not shown).
We next examined a patient-derived xenograft cell line, M7571, to determine whether
a more patient-proximal liver cancer model was amenable to restoration of gluconeogenic
gene expression after treatment with glucagon and our panel of epigenetic inhibitors. We
quantified a maximal 2-fold increase in gene expression of the gluconeogenic enzymes
under any condition tested in M7571 cells (Fig. 2.3E; pg. 64). However, contrary to the
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established SNU398 cell line, M7571 has vastly greater mRNA quantities of all 3
gluconeogenic enzymes, which was more comparable to primary human hepatocytes.
That being the case, M7571 cells do display reduced GCGR expression, akin to other liver
cancer cell lines (data not shown). This may explain why neither the epigenetic inhibitors
nor glucagon treatment substantially increased gluconeogenic gene expression, as little
epigenetic repression at the gluconeogenic gene loci coupled with low GCGR expression
would predictably make M7571 cells less responsive to epigenetic inhibitors and glucagon,
respectively.
Although the epigenetic inhibitors failed to fully restore gluconeogenic gene expression
in SNU398, cell growth was noticeably affected at specific drug concentrations and
combinations. To provide a systematic analysis of this effect, the viability of multiple liver
cancer cell lines was measured by relative ATP abundance across pharmacologically
relevant doses of each epigenetic drug (Supp. Fig. 2.3A; pg. 65). We included the FDAapproved receptor tyrosine kinase inhibitor, Sorafenib, as a clinically meaningful
comparison, as well as another experimental inhibitor, UNC0642, targeting the histone
methyltransferase, G9a, which has garnered recent appreciation for its contributions to
cancer progression (Kato et al, 2020)202. Our data reveal a broad scope of responses
across liver cancer cell lines. In general, cell lines like SNU449 exhibited increased
tolerance to epigenetic inhibitor treatment, whereas other cell lines like SNU398 displayed
greater sensitivity. Interestingly, SNU398 cells showed severe growth reduction with the
dual treatment of the EZH2 inhibitor (GSK126) and the pan-HDAC inhibitor (LBH589),
suggesting a potential therapeutic window for the drug combination (Supp. Fig. 2.3B; pg.
65).
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To further characterize the in vivo effects of EZH2/HDAC inhibition on SNU398 cells,
we generated xenograft tumors in Nu/J mice. Once tumor volume reached an average of
100-200cm3, mice were treated intraperitoneally with the epigenetic drugs at doses
previously published by other groups. Although treatment with anti-EZH2/HDAC
compounds suppressed the growth of SNU398 xenografts, significant toxicity was
prevalent, as measured by greater than 20% decreases in mouse body weight (Supp.
Fig. 2.3C, D; pg. 65).
Overall, our data indicates that while various epigenetic inhibitors may be effective in
attenuating heterochromatin repression of specific gluconeogenic gene loci under certain
conditions in liver cancer cells, we conclude that epigenetic inhibition is not sufficient for
glucagon-stimulated gluconeogenesis. Furthermore, although the epigenetic drugs
present potential therapeutic avenues from viability data in multiple cell lines in vitro, it is
unclear if this can be translated into clinical strategies or if patients would experience
better quality of life over currently deployed targeted therapies, such as Sorafenib.
SNU398 GCGR Cells Display Reduced Viability upon Glucagon Treatment through
CREB-Independent Mechanisms
Similar to the epigenetic inhibitors, while glucagon/GCGR stimulation was unable to
restore gluconeogenic gene expression to physiological levels, we did observe a
reproducible, apoptotic phenotype in SNU398 GCGR cells when treated with glucagon.
The apoptotic protein markers, cleaved PARP and cleaved Caspase-3, were both induced
specifically in SNU398 cells overexpressing GCGR upon glucagon exposure (Fig. 2.4A;
pg. 66). Additionally, overall cell number was significantly decreased in SNU398 GCGR
cells with persistent glucagon treatment (Fig. 2.4B; pg. 66). This reduction in cell growth
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was comparable to treatment with the cell cycle inhibitor, Palbociclib, and also more
pronounced than daily forskolin treatment, suggesting glucagon/GCGR may be either
more efficient in signal transduction via cAMP or engage other pathways aside from cAMP
signaling to enact tumor suppressive properties. Further validation of apoptosis
engagement in these conditions was supported by increases in PI/Annexin V-positivity
(Fig. 2.4C; pg. 66).
According to previous studies, glucagon ligand binding to GCGR approaches
saturation at the mid nanomolar range (Han et al, 2015)203. Indeed, we observed a dosedependent decrease in cell number with increasing glucagon concentration that plateaued
at 100nM and began displaying anti-proliferative effects around 3-4 days (Fig. 2.4D; pg.
66). Because serum concentration can have an impact on drug efficacy in vitro, upon
continued examination of this glucagon/GCGR phenotype, we observed an optimal
difference in growth at 5% serum, a lack of phenotype at 10% serum, and a highly
unconducive condition to cell growth at 1% serum (Fig. 2.4D, data not shown; pg. 66).
We tested this phenotype in numerous other liver cancer cell lines for glucagon/GCGR
robustness but did not measure equivalent changes in cell number compared to SNU398
at 100nM glucagon (Supp. Fig. 2.4A; pg. 67). These data suggest that SNU398
possesses a unique vulnerability to glucagon signaling, which may represent a subset of
patients.
We have previously shown that SNU398 is the only cell line tested that shows an
increase in p-CREB S133 with glucagon/GCGR (Supp. Fig. 2.2F; pg. 67). Therefore,
we surmised that CREB may be critical for a gluconeogenic-independent transcriptional
program inducing cell death, specifically in SNU398. A siRNA knockdown of CREB
protein did not rescue SNU398 GCGR cell proliferation with glucagon treatment (Supp.
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Fig. 2.4B; pg. 67), despite reasonable reductions in levels of active p-CREB S133
(Supp. Fig. 2.4C; pg. 67). Even though we did not observe a substantial effect on
viability from siCREB, we switched to a pharmacological approach with the CREB
inhibitor, 666-15, which has been shown to disrupt binding critical for transcriptional
activity (Xie et al, 2015)204 and reduce phosphorylation in AML models (Kang et al,
2015)205. However, no decrease in p-CREB S133 with drug treatment was observed
(Supp. Fig. 2.4D; pg. 67), and likewise, no rescue of cell death under the
GCGR/glucagon/666-15 condition was measured (Supp. Fig. 2.4E; pg. 67).

2.4 Discussion
Our study indicates that the liver cancer cell line SNU398 can be partially re-sensitized
to glucagon, in terms of downstream signaling and biological effect, upon supraphysiologic
levels of ectopic GCGR. This re-sensitization was unique to this specific liver cancer cell
line as others did not show a similar phenotype. Concordantly, we hypothesize that liver
cancer cells themselves would be largely unaffected by circulating glucagon directly.
Although, it remains to be seen if normal hepatocytes stimulated to synthesize glucose by
glucagon secretion could provide local glucose, as tumor cells are thought to regulate
metabolism of others cells within the microenvironment to suit their nutritional needs
(Comito et al, 2020)206. In this manner, gluconeogenesis could actually be oncogenic at
the systemic level through nutrient partitioning and/or competition between normal and
tumor cells. Diabetes is a risk factor for liver cancer development and is commonly
characterized by abnormally high glucagon signaling, likely as a result of decreased insulin
sensitivity (Haedersdal et al, 2018) 207. In diabetic patients with liver cancer, we believe it
important to study the potential cell non-autonomous effects of normal, glucagon56

responsive hepatocytes as to their ability to facilitate tumor cell growth by releasing
glucose into the tumor microenvironment.
In terms of inducing gluconeogenesis within tumor cells themselves, our data suggests
that this may be an unlikely therapeutic approach for liver cancer. The mRNA expression
of GCGR, G6PC, FBP1, and PCK1 are decreased in patient tumors and heavily silenced
in many established liver cancer cell lines. For these cell lines, neither epigenetic agents
nor stimulation of glucagon signaling was sufficient to restore physiological gluconeogenic
gene expression (which we infer does not reduce glycolytic flux), suggesting multiple
and/or redundant mechanisms of transcriptional repression. In addition, modulation of
protein stability and enzyme activity should also be considered. Taken together, this
regulatory complexity may account for why cell lines are still unable to fully engage the
entire gluconeogenic pathway despite enforced glucagon/GCGR signaling and inferred
improvement of chromatin accessibility.
However, this is not to say that individual gluconeogenic enzymes could not have
distinct roles under certain metabolic circumstances. For example, PCK1 expression and
activity could be induced to funnel extra anaplerotic intermediates from the TCA cycle into
serine/glycine biosynthesis to support one-carbon

metabolism. FBP1-catalyzed

production of fructose-6-phosphate can enter the pentose phosphate pathway to support
nucleotide, lipid, and antioxidant synthesis. However, it is not clear how G6PC-regulated
loss of intracellular glucose could promote survival under any situation. Interestingly,
G6PC was the only gene not increased upon any combination of glucagon/GCGR or
epigenetic inhibition, suggesting that the de-phosphorylation of glucose-6-phosphate, and
its subsequent loss or lack of utilization, has no advantage for cell viability under cellular
stress.
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Three unresolved questions pertain to (1) the lack of gluconeogenic gene expression
in glucagon-treated SNU398 GCGR cells, (2) mechanistic nature of the GCGR/glucagon
phenotype in SNU398, and (3) this discrepancy between other liver cancer cell lines
tested. While p-CREB S133 has been shown to be important for stimulating G6PC and
PCK1 expression through recruitment of transcriptional coactivators such as CBP (Kwok
et al, 1994)208, there are certainly a number of other transcription factors, aside from
epigenetic modifiers, that can also directly regulate gluconeogenic gene expression.
Chromatin interactions between FOXO1 and PGC1α (Puigserver et al, 2003)209, HNF4a
and PGC1α (Rhee et al, 2003)210, as well as nuclear glucocorticoid receptors with RXRs
(Grontved et al, 2013)211, can also localize at gluconeogenic gene promoters to
positively control expression. A successful gluconeogenic response in normal
hepatocytes may require inputs from all of these factors, whereas insufficient
components of these transcriptional machineries may embody cancer cells. This may
explain why glucagon signaling alone is not enough in a SNU398 GCGR cells.
Mechanistically, CREB inhibition was insufficient to rescue the growth phenotype of
glucagon-stimulated SNU398 GCGR cells. This may imply that another factor
downstream of PKA, or multiple factors including CREB, are responsible. Utilizing
pharmacological approaches, we attempted to target PKA, which has many other targets
besides CREB, and Ca+2-activated CAMKII, which has also been shown to be an
important effector of glucagon signaling. However, neither inhibition of PKA nor CAMKII
resulted in an increase in SNU398 GCGR cell proliferation upon glucagon treatment.
Because glucagon signaling has widespread pleotropic effects on cell metabolism,
including glycogenolysis and lipid processing, it may be necessary to unbiasedly
address metabolic rewiring before performing precise rescue experiments. Therefore,
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future studies on glucagon signaling in liver cancer could analyze metabolomics profiling
of SNU398 GCGR cells with or without glucagon, compared to a cell line that is
unresponsive, regardless of glucagon treatment. Differential analysis of metabolites may
reveal the likely cause of sensitivity in SNU398 cells, answering a potentially impactful
question of how glucagon signaling could disrupt cell viability independent of
gluconeogenesis.
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Figure 2.1 – HCC cell lines are dependent on exogenous glucose / lipid dependency and express low levels of the
glucagon receptor, GCGR. (a) Cell proliferation assays of two cell lines, SNU398 and Huh7, at the indicated time point
and nutrient conditions. Data represents a single experiment with 3 biological replicates. Red dashed line denotes fold
change of 1, which refers to the starting number of cells. (b) Simplified Glucagon/GCGR signaling transduction. GCGR:
g-coupled glucagon receptor, Ac: adenyly cyclase, cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, pCREB: phosphorylated cAMP-response element binding protein. (c) Normalized RNA-seq values for GCGR in human
HCC compared to normal liver. Data obtained from TCGA. ****: p<0.0001, unpaired two-tailed t test. n = 50(normal) and
374(tumor). (d) qPCR mRNA expression of GCGR in HCC cell lines compared to Primary Human Hepatocytes (PHH).
Data represent a single experiment with 3 biological replicates (3 separate RNA samples). ****: p<0.0001, ordinary oneway ANOVA with Dunnett’s multiple comparisons test. (e) Kaplan-Meier plot of overall survival probability between high
and low GCGR expression in liver cancer patients. Graph was generated using the website: https://kmplot.com.
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Supplementary Figure 2.1. Liver cancer cells display hypersensitivity to long- and short-term glucose and lipid
withdrawal, potentially explained by low gluconeogenic gene expression. (a) Cell number-based proliferation assays
of HCC cell lines cultured in different concentrations of glucose at the indicated time point. Data represent a single
experiment with 3 biological replicates. (b) Cell number-based proliferation assays of HCC cell lines cultured in different
concentrations of lipids (oleic acid) at the indicated time point. Data represent a single experiment with 3 biological
replicates. (c) ATP-based cell viability assay of HCC cell lines cultured across a wide range of glucose concentrations.
Data points represent the average of 6 biological replicates. (d) ATP-based cell viability assay of HCC cell lines cultured
across a wide range of oleic acid concentrations. Data points represent the average of 6 biological replicates. (e)
Simplified schematic of opposing glycolytic (red) and gluconeogenic (blue) pathways. G6PC: glucose-6-phosphatase, HX:
hexokinase, G6P: glucose-6-phosphate, FBP1: fructose-1,6-bisphophatase 1, PFK: ATP-dependent 6phosphofructokinase, F-1,6-BP: fructose-1,6-bisphophatase, PCK1: phosphoenolpyruvate carboxykinase (cytosolic), PK:
pyruvate kinase. (f) qPCR mRNA expression of gluconeogenic genes in HCC cell lines compared to Primary Human
Hepatocytes (PHH). Data represent a single experiment with 3 biological replicates (3 separate RNA samples). ****:
p<0.0001, ordinary one-way ANOVA with Dunnett’s multiple comparisons test. (g) Normalized RNA-seq values for
gluconeogenic genes in human HCC compared to normal liver. Data obtained from TCGA. ****: p<0.0001, *: p<0.05,
unpaired two-tailed t test. n = 50(normal) and 374(tumor). All error bars: +/- SEM. (h) Kaplan-Meier plot of overall survival
probability between low and high expression of gluconeogenic enzymes. Graphs were generated using the website:
https://kmplot.com.
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Figure 2.2. GCGR overexpression partially sensitizes SNU398 to glucagon signaling. (a) qPCR mRNA levels of
GCGR in SNU398, following lentiviral CMV-driven mammalian expression, compared to Primary Human Hepatocytes
(PHH). Data represent a single experiment with 3 biological replicates (3 separate RNA samples). eGFP used as a
control. (b) Protein assessment of GCGR and eGFP overexpression in SNU398. Lysate number denotes independent
protein sample. (c) Quantification of cAMP in SNU398 expressing either eGFP or GCGR and treated with 100nM
glucagon (100G) at the indicated condition and time. Data points represent a single experiment of 2 technical replicates.
veh: vehicle (0.05M acetic acid), 20F: 20uM forskolin (positive control). (d) Protein analysis of downstream effectors of
cAMP signaling in SNU398 cells expressing either eGFP or GCGR and treated with 100nM glucagon (+) at the indicated
condition and time. (-): vehicle treated. (e) Protein localization of p-CREB following glucagon treatment of SNU398 cells
expressing either eGFP or GCGR. (f) qPCR mRNA expression of G6PC in SNU398 cells expressing either eGFP or
GCGR and treated with 100nM glucagon (100G) at the indicated condition and time. Data represent a single experiment
with 3 biological replicates (3 separate RNA samples). Error bars: +/- SEM. veh: vehicle (0.05M acetic acid). ns: not
significant, p>0.05, ordinary one-way ANOVA with Tukey’s multiple comparisons test.
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Supplementary Figure 2.2. Constitutive GCGR expression in SNU398, but not other liver cancer cell lines,
stimulates PKA activity in response to glucagon without inducing gluconeogenic gene expression. (a)
Quantification of cAMP in SNU398 expressing either eGFP or GCGR and treated with 100nM glucagon (100G) at the
indicated condition and times. Each graph represents an independent experiment with 2 technical replicates. DMSO:
dimethylsulfoxide, HOAc: 0.05M acetic acid, 20F: 20uM Forskolin (positive control), veh: vehicle (0.05M acetic acid), 20F:
20uM forskolin (positive control). (b) Long-term protein analysis of downstream effectors of cAMP signaling in SNU398
cells expressing either eGFP or GCGR and treated with 3 different concentrations of glucagon. Black triangles denote
increasingly equivalent concentrations of vehicle compared to glucagon (red triangles). (c) qPCR mRNA expression of
G6PC in SNU398 cells expressing either eGFP or GCGR and treated with 100nM glucagon (100G) at the indicated
condition and time. Data represent a single experiment with 3 technical replicates (1 RNA sample). Error bars: +/- SD.
veh: vehicle (0.05M acetic acid). (d) qPCR mRNA levels of GCGR in HCC cell lines compared to Primary Human
Hepatocytes (PHH). Same pLenti-CMV-GCGR or pLenti-CMV-eGFP lentivirus as SNU398 was used for stable
expression. Data represent a single experiment with 2 biological replicates (2 separate RNA samples). (e) Quantification
of cAMP in HCC cell lines expressing either eGFP or GCGR and treated with 100nM glucagon (100G) at the indicated
condition and time. Data points represent a single experiment of 2 technical replicates. veh: vehicle (0.05M acetic acid),
20F: 20uM forskolin (positive control). (f) Protein analysis of downstream effectors of cAMP signaling (PKA substrates) in
HCC cell lines expressing GCGR and treated with either vehicle (0.05M acetic acid, (-)) or 100nM glucagon (+) at the
indicated condition and time. (g) qPCR mRNA levels of GCGR and gluconeogenic enzyme genes in cryopreserved
primary human hepatocytes (cPHH) treated with 100nM glucagon (100G) at the indicated condition and time. Data
represent a single experiment with 2 biological replicates (2 separate RNA samples).
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Figure 2.3. Epigenetic inhibitors fail to fully restore gluconeogenic gene expression with or without glucagon. (a)
Diagram of epigenetic drugs and their targets. GSK126: EZH2 (enhancer of zeste homolog 2) inhibitor, SAM: S-adenosylL-methionine, SAH: S-adenosyl homocysteine, H3K27me3: histone 3 lysine 27 trimethylated, LBH589: pan-HDAC
(histone deacetylase) inhibitor, H3K27Ac: histone 3 lysine 27 acetylated, Decitabine: DNA methylation (DNMT - DNA
methyltransferase) inhibitor, 5mC: 5-methylcytosine. (b) Protein analysis of epigenetic inhibitor efficacy in SNU398 eGFPexpressing cells at the indicated drug concentrations, culture conditions, and time. (c) qPCR mRNA levels of
gluconeogenic genes in SNU398 expressing eGFP and treated with epigenetic inhibitors at the concentrations used in (b),
condition, and time. Data represent a single experiment with 2 biological replicates (2 separate RNA samples). ND: not
detected. (d) qPCR mRNA levels of G6PC, FBP1, and PCK1 in SNU398 GCGR-overexpressing cells treated with
glucagon plus combinations of epigenetic drugs at the indicated condition and time. Data represent a single experiment
with 3 technical replicates (1 RNA sample). Error bars: +/- SD. (-): no drug, 100G: 100nM glucagon, vehicle: 0.035% of
0.05M acetic acid, EZH2i: 1uM GSK126, HDACi: 10nM LBH589, DNMTi: 5uM Decitabine, triple: 1uM GSK126 + 10nM
LBH589 + 5uM Decitabine. (e) Same qPCR mRNA analysis as in (d) but using the liver cancer patient-derived cell line,
M7571.
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Supplementary Figure 2.3. Epigenetic inhibitors reduce cell viability across multiple HCC cell lines but display high
toxicity in vivo. (a) ATP-based cell viability assays performed on HCC cell lines treated with serially diluted (1:3)
concentrations of epigenetic inhibitors at the indicated condition and time. Data points represent the average of 6
biological replicates. Error bars: +/- SEM. DMSO used a vehicle control. Note, no maximal drug concentration included
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the indicated condition and time. (b) Cell proliferation assay of SNU398 cells either expressing eGFP or GCGR and
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Supplementary Figure 2.4. Glucagon/GCGR only decreases cell viability in SNU398 through an unknown
mechanism independent of CREB. (a) Cell proliferation assays on liver cancer cell lines either expressing eGFP or
GCGR and treated with 100nM glucagon at the indicated condition and time. Data points represent 3 biological replicates.
Error bars: +/- SEM. (b) Crystal violet assay on SNU398 cells either expressing eGFP or GCGR, treated with 100nM
glucagon (100G), and transfected with 25nM of a small interfering RNA molecular targeting CREB1 (siCREB). Cells were
initially treated with glucagon for 3 days and then transfected with siCREB without any further treatment. siNTC (25nM):
non-targeting control, veh: vehicle (0.05M acetic acid). (c) Protein analysis of siRNA efficacy in SNU398 cells either
expressing eGFP or GCGR and treated with 100nM glucagon. Samples harvested at the 7-day time point as illustrated in
the previous figure panel. siCycloB (25nM): Cyclophilin B (positive control for transfection protocol). (d) Protein
assessment of the target efficacy of CREB antagonist, 666-15, in SNU398 cells either expressing eGFP or GCGR and
treated with or without 100nM glucagon. (e) PI/Annexin V flow cytometry analysis of SNU398 cells expressing either
eGFP or GCGR and treated with either 100nM glucagon, 0.5uM 666-15, or the combination. Data points represent
average of 3 biological replicates. Error bars: +/- SEM. 10ug/ml blasticidin used as a positive control. ns: not significant, **:
adjusted p=0.0055, ordinary one-way ANOVA with Tukey’s multiple comparisons test.
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Table 2.1 – Cell line models of liver cancer.
Cell Line

Sex,
ethnicity,
age

Cancer
subtype, grade,
treatment
status

Hepatitis
B status

Hotspot
mutations
(putative
drivers)

Telomerase
amplification
(promoter
mutation)

Chromosome
Y loss

SNU182

M, Asian,
24

HCC, (?), naive

+

P53S215I/S215I

WT

No

SNU387

F, Asian,
41

Pleomorphic
HCC, (?), postTACE with
doxorubicin /
mitomycin-C

+

NRASQ61K/+

AMP (124C>T)

No

P53K164*/K164*

SNU398

M, Asian,
42

HCC, (?), postTACE with
doxorubicin +
mitomycin-C

+

CTNNB1S37C/+

WT

Yes

SNU423

M, Asian,
40

Pleomorphic
HCC, III/IV, postTAC with
doxorubicin

+

P53SS/SS
(splice site)

AMP (124C>T)

No

SNU449

M, Asian,
52

HCC, II-III/IV,
naive

+

P53A161T/A161T

WT

Yes

SNU475

M, Asian,
43

HCC, (?), naive

+

P53N239D,

AMP (124C>T)

Yes

G262D/+

Huh7

M, Asian,
57

Hepatoma, (?),
(?)

-

P53Y220C/Y220C

WT

No

Hep3B

M, Black,
8

HCC, (?), (?)

+

Axin1R146*/R146*

WT

Yes

HepG2

M, White,
15

Hepatoblastoma,
(?), (?)

-

NRASQ61L/+

AMP (124C>T)

No

PLC

M, Black,
24

Hepatoma, (?),
(?)

+

P53R249S/R249S

WT

Yes

68

SK-HEP-1

M, White,
52

Adenocarcinoma
(liver endothelial
origin), (?), naive

BRAFV600E/+

(-)

69

WT

Yes

CHAPTER 3: Glycogen Metabolism is Dispensable for Tumor Progression in Clear
Cell Renal Cell Carcinoma

This chapter has been adapted from:
(1) Hong X, Song J, Godfrey J, Riscal R, Skuli N, Nissim I, and Simon MC. Glycogen
metabolism is dispensable for tumor progression in clear cell renal cell
carcinoma. Nat Metab. 2021. Mar;3(3):327-336. doi: 10.1038/s42255-021-00367x.

Additionally, I would like to clearly state that the majority of experiments performed, as
described in this chapter, were done by the lead authors of the aforementioned paper
(Hong Xie, and Jun Song). Following their departure from the laboratory, I completed the
final xenograft experiment (with significant help from Nico Skuli and Romain Riscal),
submitted the manuscript, performed experiments based on reviewer feedback, and
wrote the final version of the manuscript.
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3.1 Abstract
Glycogen accumulation is a highly consistent, distinguishable characteristic of clear
cell renal cell carcinoma (ccRCC) (Ericsson and Seljelid, 1966)212. While elevated
glycogen pools might be advantageous for ccRCC cells in nutrient deprived
microenvironments to sustain tumor viability, data supporting a biological role for
glycogen in ccRCC are lacking. Here, we demonstrate that glycogen metabolism is not
required for ccRCC proliferation in vitro nor xenograft tumor growth in vivo. Disruption of
glycogen synthesis by CRISPR-mediated knockout of glycogen synthase 1 (GYS1) has
no effect on proliferation in multiple cell lines, regardless of glucose concentrations or
oxygen levels. Similarly, prevention of glycogen breakdown by deletion or
pharmacological inhibition of glycogen phosphorylases B and L (PYGB and PYGL) has
no impact on cell viability under any condition tested. Lastly, in vivo xenograft
experiments using the ccRCC cell line, UMRC2, reveal no significant alteration in tumor
size or volume when glycogen metabolism is altered, largely phenocopying our in vitro
observations. Our findings suggest glycogen buildup in established ccRCC tumor cells is
likely to be a secondary, and apparently dispensable, consequence of constitutively
active HIF-1 signaling.
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3.2 Materials and Methods
Primary Patient Samples
Deidentified fresh-frozen matched ccRCC tumor/normal samples were obtained from
the Cooperative Human Tissue Network (CHTN), which operates with the review and
approval of their local Institutional Review Boards.
Cell Culture and Cell Proliferation Assays
Human ccRCC cell lines (UMRC2, 786-O, RCC4, and UOK101) were obtained from
the American Type Culture Collection (ATCC) and cultured in DMEM supplemented with
10% FBS and Penn/Strep. All cells were routinely confirmed to be Mycoplasma negative
(MycoAlert; tested every 3 months). For culture conditions with various glucose
concentrations, cells were maintained in glucose-free DMEM supplemented with 10%
dialyzed FBS (cat. 100-108, GeminiBio) and indicated concentrations of glucose.
Hypoxic conditions (0.5% O2 and 1% O2) were achieved in a Baker Ruskinn in vivo2
workstation, by supplementing ambient air with balanced N 2 and CO2. For lipid depletion
experiments, cells were cultured in charcoal-stripped FBS (cat. 900-123, GeminiBio).
Cell proliferation assays were performed using WST-1 reagent (cat. 5015944001,
Sigma-Aldrich): cells were plated in 96-well plates at 800-1,500 cells/well and allowed to
attach overnight. The medium was changed according to indicated culture conditions on
the following day, which was considered as Day 0. Cells were subjected to WST-1 assay
following manufacturers protocol on each day. Cell proliferation rate was represented by
relative absorbance, which was determined by normalizing to the absorbance number at
Day 0 of the assay. Additional proliferation assays were performed using Trypan Blue
exclusion and labeled as “Total Live Cells” on the Y axis (see Figure 3.3j and Extended
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data figure 3.4h (upper panel)). Cells were plated in 6-well plates at 50,000-100,000
cells/well and allowed to adhere overnight. The next day, cells were given fresh medium
and cultured in the experimental conditions. At each time point, cells were trypsinized
and resuspended in FBS-containing medium. Cell/trypan blue mixtures were counted by
a Countess II (Life Technologies) and corrected for dilutions.
Boyden Chamber Cell Migration Assay
50,000 UMRC2 cells were seeded in 0.1 ml of 0% FBS, DMEM (0mM glucose) per
transwell polycarbonate insert with 8μm pores (cat. 3422, Corning). Approximately 0.6
ml of either 0% or 10% FBS DMEM (25 mM glucose) was added to each bottom well.
Following overnight incubation, inserts were washed with PBS and then gently scraped
with a cotton swab (topside only). Next, membrane inserts were incubated in
approximately 0.6 ml of 0.5% crystal violet (cat. C6158, Sigma-Aldrich) in 20% methanol
for 10 minutes. Transwells were washed twice with PBS and allowed to dry overnight.
Membrane inserts were cut out and mounted on a microscope slide for imaging.
Plasmids, Lentivirus Production, and Viral Transduction
For shRNAs, the lentiviral vector pLKO.1 SCR (scrambled shRNA plasmid no.
17920) was from Addgene. shRNAs targeting HIF1A (shHIF1A_52, shHIF1A_9) and
EPAS1 (shHIF2A_6, shHIF2A_7) were described previously 9. For genetic knockout
using CRISPR/Cas9, the lentiviral vector LentiCRISPR v2 (plasmid no. 52961) and
LentiCRISPRv2GFP (plasmid no. 82416) were obtained from Addgene. Human singleguide RNAs (sgRNA) targeting GYS1 #1 (GAACGCAGTGCTCTTCGAAG), #3
(CTACACGGTGCTGCAGACGA); PYGL #1 (GAAGCTGCTCCCTCGACATT), #3
(TAGCCACGCCATTCACAGCA), and #4 (GAGGACCCGGGAGATGTTCT) along with a
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control sgRNA targeting mouse Rosa26 locus (AAGATGGGCGGGAGTCTTCT) were
cloned into LentiCRISPR v2 plasmid, while sgRNAs targeting PYGB #1
(CAACGTGGGAGACTACATCG) and #4 (CCACCTTCTCCACGTCCACC) along with a
control sgRNA targeting LacZ (TCGTTTTACAACGTCGTGAC) were cloned into
LentiCRISPRv2GFP plasmid. To produce lentiviruses, 293T cells were co-transfected
with shRNA or CRISPR plasmid of interest along with packaging plasmids psPAX2 and
pMD2.G using FuGENE 6 transfection reagent (cat. E2691, Promega). Lentiviruses
were collected 48 hours after transfection. Viruses were used with 8 μg/ml polybrene for
infection. For the LentiCRISPR v2 system, cells were selected with 4 μg/ml puromycin
for 5 days to establish stable cell lines, while for LentiCRISPRv2GFP system, top 50%
GFP positive cells were sorted for future culture and analysis. For PYGB overexpression
analyses, 25 l of pre-made, constitutive expression lentiviral vector, pLOC-PYGB (cat.
OHS5899-202619959, Dharmacon), were added to 1.5 ml of UMRC2 cells. Cells were
selected with 5 g/ml blasticidin for 4 days prior to subsequent experimentation.
Western Blot Analysis
Cells and tumor tissue samples were lysed in RIPA lysis and extraction buffer (cat.
89900, ThermoFisher Scientific) containing Roche complete ULTRA
Protease/Phosphatase Inhibitor (cat. 05892791001). Protein concentration was
quantified with Pierce BCA Protein Assay Kit (cat. 23225, ThermoFisher Scientific).
Isolated proteins were resolved by SDS-PAGE, and Western blot analysis was
performed. All primary antibodies were diluted 1:1,000 in 5% w/v nonfat milk. Blots were
incubated with primary antibodies overnight at 4°C. GYS1 (cat. ab40810) and ACTIN
(cat. ab3280) antibodies were from abcam; HIF-1α antibody was from Cayman (cat.
10006421); HIF-2α antibody was from Novus Biologicals (cat. NB100-122); GAPDH
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antibody was from Cell Signaling Technology (cat. 2118); PYGL antibody was from
Sigma (cat. HPA000962); PYGB antibody was from proteintech (cat. 12075-1-AP).
Primary antibodies were detected using horseradish peroxidase–conjugated secondary
antibodies from Cell Signaling Technology (cat. 7074) followed by exposure to enhanced
chemiluminescence substrate (cat. NEL103001EA, PerkinElmer) or SuperSignal West
Femto Maximum Sensitivity Substrate (cat. 34095, ThermoFisher Scientific).
Reagents
GPi (pan-glycogen phosphorylase inhibitor) CP316819 was purchased from Tocris
(cat. 3542).
TCGA RNA-seq Analysis
RNA-seq data for ccRCC and normal kidney samples were downloaded and
analyzed from the TCGA on April 2, 2013 as previously described 17. Differential gene
expression analysis of tumor and normal samples were performed using DeSeq
(Bioconductor Version 2.12). Box and whisker plots correspond to 5-95th percentiles
(bars), 25-75th percentiles (box), and median (line in box).
RNA Extraction, Real-Time Quantitative RT-PCR Analysis
Total RNA was isolated using the RNeasy Mini Kit (cat. 74104, QIAGEN), and cDNA
was synthesized using the High-Capacity RNA-to-cDNA Kit (cat. 4387406,
ThermoFisher Scientific). Quantitative reverse-transcription PCR (qRT-PCR) was
performed on a ViiA7 Real-Time PCR system from Applied Biosystems. Predesigned
TaqMan primers were obtained from ThermoFisher Scientific for the following genes:
TBP (Hs00427620_m1), ACTB (Hs01060665_g1), HIF1A (Hs00153153_m1), HIF2A
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(Hs01026149_m1), CCND1 (Hs00765553_m1), PDK1 (Hs00176853_m1), GYS1
(Hs00157863_m1), PYGB (Hs00765686_m1), PYGL (Hs00958087_m1), PYGM
(Hs00989942_m1), and RNA18S/45S (Hs03928985_g1).
Glycogen Quantification
Glycogen levels were measured using the Glycogen Assay Kit II (Colorimetric) from
abcam (cat. Ab169558). Briefly, cells or tumor tissues were homogenized with dH2O on
ice and then boiled for 10 min. Homogenates were then spun at 13,000 rpm for 10 min
and supernatants were assayed for glycogen content. Results were normalized by
protein content.
Matrigel-Based Spheroid Growth Assay
Matrigel-based 3D spheroids formation technique was described previously (Vinci et
al, 2012)213. Briefly, 3,000 cells per well were plated in a 96-well ultra-low attachment
plate (cat. CLS3474, Sigma) along with DMEM plus 10% FBS and 2.5% matrigel (cat.
354234, Corning). Plates were centrifuged at 1,500 rpm to promote spheroid formation,
and then imaged at indicated time points using the EVOS FL Imaging System. Final
pictures were taken at 40X magnification. Spheroid volume was calculated using a
previously published ImageJ macro (Ivanov et al, 2014)214.
Metabolites and Glycogen Tracing
Mass spectrometry-based metabolomics analysis of primary ccRCC was performed
with Metabolon (Extended Data Figure 3.1b), as previously described (Li et al, 2014)137.
In addition, publicly available metabolomics data from Hakimi, et al. 215 were downloaded
and values normalized to normal kidney tissue (Figure 3.1c). For the glycogen tracing
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experiment, cells were seeded at 50-70% confluency in 15 cm dishes (Day 0). The
following day (Day 1), media was changed to 1% dialyzed FBS, 0 mM glucose DMEM,
to deplete unlabeled glycogen stores, and incubated at 1% O2 overnight. The next day
(Day 2), 25mM of uniformly labeled

13

C ([U-13C]) glucose (cat. CLM-1396-1, Cambridge

Isotope Lab.) was added to cells, to regenerate glycogen with labeled glucose, and
cultured overnight at 1% O2. The following day (Day 3), media was aspirated and cells
were washed twice with 1X PBS to remove labeled glucose. Cells were then incubated
at 1% O2 overnight in fresh 1% dialyzed FBS, 0 mM glucose DMEM with 10 M of GPi
(see reagents) to prevent the breakdown of labeled glycogen. On the last day (Day 4),
media was changed to either DMSO control or 10 M GPi in fresh 1% dialyzed FBS, 0
mM glucose DMEM and cultured for 0, 3, or 6 hrs. At these time points, cell metabolites
were extracted by (1) aspirating media, (2) washing twice with cold PBS, (3) adding 0.5
ml of 4% perchloric acid, and (4) transferring semi-frozen supernatant to microfuge
tubes. All samples were submitted to the Metabolomic Core at the Children’s Hospital of
Philadelphia for LC/MS analysis. Data are normalized to internal metabolite controls and
presented as atomic percent excess (APE) to describe the percentage of a

13

C-labeled

metabolite relative to its unlabeled form.
Periodic Acid Schiff Staining
Glycogen was detected in tumor sections following a standardized periodic acid
Schiff (PAS) staining technique, which was performed by the Molecular Pathology &
Imaging Core at the University of Pennsylvania.
Mice and Xenograft Experiments
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Xenograft tumor experiments were approved by the Animal Care and Use
Committee at the University of Pennsylvania. 200μL of 5 million UMRC2 control or
knockout cells were subcutaneously injected into opposing flanks of the same 4-6 week
old female NIH-III nude mouse (strain code 201, Charles River), in a 1:1 mixture of
DMEM and matrigel. Once palpable tumors were established, tumor volume was
monitored by caliper measurements. Upon completion of the experiment, the animals
were sacrificed by CO2 inhalation, followed by cervical dislocation, and xenograft tumors
were dissected for downstream analyses.
Statistics and Reproducibility
Experimental significance was determined by P value, whereby any value 0.05 or
below was considered mathematically unlikely to be random. Unpaired, two-tailed
Student’s t test was used for simple column analyses between two conditions, unless
comparing matched samples, such as from same patient or mouse, in which case paired
t tests were employed. Two-way ANOVA with Sidak’s multiple comparison correction
test was used for more complex group analyses and multiple conditions (see individual
figure legends). All graphs and statistical inquiries were generated using GraphPad
Prism versions 7.0 - 9.0.1 (current). For all qRT-PCR and glycogen quantifications, data
is derived from technical replicates, presented as mean +/- standard deviation (SD), and
represents results of reproducible experiments. For all growth curves and metabolite
tracing, data is derived from biological replicates and presented as mean +/- standard
error of the mean (SEM). For box plots, graphs are shown with all points, center line as
the median, box bounds as 25th and 75th percentiles, and whiskers as either 5th and 95th
percentiles or minimum and maximum values (see individual figure legends). For all
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experiments shown, similar results were obtained across multiple cell lines (see
Extended Data for additional cell lines) and reproduced at least once by multiple authors.
Data Availability
Human patient ccRCC tumor and normal tissue RNA-seq dataset was obtained from
The Cancer Genome Atlas (TCGA) at https://www.cbioportal.org (see above TCGA
RNA-seq analysis for further details). Human patient ccRCC tumor and normal
metabolomics dataset was obtained from Hakimi, et al 16 (https://www.cell.com/cancercell/comments/S1535-6108(15)00468-7#secsectitle0145). All data that support the
findings of this study are available from the corresponding author upon request.

3.3 Results
Glycogen Synthesis and Breakdown are Hyperactive in ccRCC Tumors
To address whether the glycogen pathway (Fig. 3.1a; pg. 90) is consistently altered
in ccRCC, elevated glycogen levels were confirmed in patient tumors compared to
matched normal kidney tissue (Fig. 3.1b; pg. 90). Comparable quantities of glycogen
were also detected in six cell line models of ccRCC: 786-O, UOK101, 769P, UMRC2,
RCC4, and RCC10 (Extended Data Fig. 3.1a; pg. 91). To provide a more
comprehensive and informative picture of glycogen production and degradation, we
queried our previously generated metabolomic data137 on the same patient paired tumor
and normal samples for glycogen-related metabolites. Many products of glycogen
metabolism were relatively increased in ccRCC, including glucose-1-phosphate, and
oligosaccharide branch intermediates, i.e. maltose, maltotriose, and maltotetraose (Fig.
3.1c; pg. 90). These findings are consistent with a separate metabolomics assessment
79

of 138 matched ccRCC/normal tissue pairs we further analyzed 215 (Extended Data Fig.
3.1b; pg. 91). Lastly, TCGA RNA-seq analysis revealed that all genes involved in
glycogen metabolism are differentially expressed, including overexpression of those
encoding critical synthetic enzymes (PGM1, GYS1, and GBE1), and catabolic enzymes
(PYGL and PYGM) (Fig. 3.1d, e; pg. 90). Some patients appear to stratify into high or
low levels of expression (relative to normal kidney), which may indicate that elevated
glycogen abundance is a result of a variety of transcriptional inputs. This was also
consistent with our patient samples, where tumors sometimes showed higher or lower
expression of a given gene related to glycogen metabolism compared to normal tissue
(Extended Data Fig. 3.1c; pg. 91). Nevertheless, based on increased glycogen content,
elevated glycogen-derived metabolites, and differential expression of glycogen modifying
genes, we concluded that glycogen metabolism is significantly deregulated in ccRCC
tumors.
Elevated Glycogen Synthesis Enzyme, GYS1, is Regulated by HIF1α, but has No Effect
on Tumor Proliferation in ccRCC Models
To determine whether glycogen serves a key biological role in ccRCC, the ratelimiting enzyme, glycogen synthase, was initially evaluated as it directly controls
glycogen synthesis (Fig. 3.2a; pg. 92). In mammalian cells, glycogen synthase has two
isoforms, GYS1 (expressed in skeletal muscle and other tissues) and GYS2 (expressed
predominately in the liver) (Zois et al, 2016)216. Analysis of TCGA RNA-seq database
and primary samples revealed that GYS1 mRNA and protein levels were significantly
increased in tumor samples (Fig. 3.2b, c; pg. 92). Since constitutive activation of HIF-α
proteins through pVHL loss of function is a major driver of ccRCC pathogenesis 176, the
capability of HIFs to facilitate increased GYS1 transcription was assessed. Based on
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shRNA knockdown, GYS1 mRNA levels and glycogen deposition were selectively
controlled by HIF-1α in HIF-1α expressing cells (H1H2) (Extended Data Fig. 3.2a, b;
pg. 93), and HIF-independent mechanisms in HIF-2α only expressing cells (H2)
(Extended Data Fig. 3.2c; pg. 93). Based on previous transcriptomic analyses4,
expression levels of GYS1, PYGB, PYGL, and PYGM were not significantly different
between H1H2 and H2 ccRCC tumors. Additionally, 786-O cells stably re-expressing
pVHL did not show altered expression of glycogen metabolic enzymes (Extended Data
Fig. 3.2c; pg. 93), confirming regulation by pathways other than the HIFprolylhydroxylation-pVHL system when HIF-1α is absent.
In addition to transcriptional regulation, post-translational control of GYS is achieved
through phosphorylation, alternating between the phosphorylated inactive state and
dephosphorylated active state (Extended Data Fig. 3.2d; pg. 93)216. GYS
dephosphorylation is catalyzed via hydrolysis by protein phosphatase-1 (PP1) which is
bound to glycogen targeting subunit proteins, protein phosphatase 1 regulatory subunit 3
(PPP1R3) (Munro et al, 2005)217. At least seven distinct genes encode PPP1R3:
PPP1R3A-G, that are differentially expressed across tissues 216. Previous studies
demonstrated that PPP1R3C overexpression promotes glycogen accumulation in
different tissues, suggesting its essential role in activating GYS and subsequent
glycogen buildup (Shen et al, 2010; Yang et al, 2015; Jurczak et al, 2007; Greenberg et
al, 2003)218-221. In ccRCC tumors, PPP1R3B and PPP1R3C expression was elevated in
all tumor stages (Extended Data Fig. 3.2e; pg. 93). Consistent with glycogen buildup,
these data suggest that elevated GYS1 mRNA and protein levels in ccRCC is a result of
HIF-1α stabilization, whereas enhanced GYS1 activity is due to greater expression of
accessory proteins important for GYS1 dephosphorylation.
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To assess the functional consequences of elevated GYS1 expression and glycogen
accumulation in ccRCC, GYS1 protein was reduced using two independent sgRNAs in
multiple cell lines with variable baseline glycogen levels (UMRC2, 786-O, RCC4, and
UOK101, Extended Data Fig. 3.1a; pg. 91). As shown in Figure 3.2d and Extended
data figure 3.3a, both sgRNAs targeting GYS1 robustly decreased GYS1 protein levels,
resulting in rapid glycogen depletion in these cells (Fig. 3.2e, Extended Data Fig. 3.3b;
pgs. 92 and 94). We hypothesized that cell proliferation would be inhibited if cells were
unable to store glucose as glycogen for future use under acute conditions of nutrient
deprivation. Surprisingly, GYS1 KO did not affect growth in UMRC2 cells, regardless of
culture conditions (25mM vs. 0mM glucose, 21% vs. 1% O2, 1% FBS) (Fig. 3.2f; pg. 92).
UMRC2 GYS1 WT and KO cells were also embedded in Matrigel for spheroid growth to
better mimic nutrient gradients and tissue pressure observed within the tumor
environment. Again, GYS1 KO did not affect spheroid volume during the course of this
assay (Fig. 3.2g; pg. 92). The same trend was observed in spheroid assays for 786-O
cells, as well as in 2-D proliferation assays for RCC4 and UOK101 cells (Extended Data
Fig. 3.3c, d; pg. 94). Of note, both GYS1 WT and KO UOK101 cells were particularly
sensitive to growth in 25mM glucose at 1% O2 after 2 days due to lactic acid
accumulation. These results suggest that although GYS1 mRNA and protein levels are
overexpressed in ccRCC patient tumors and cell lines and associated with a
concomitant accumulation in glycogen, neither GYS1 nor glycogen production is
required for 2-D or 3-D growth under normal and tumor-relevant stress conditions.
Glycogen Breakdown Requires Both PYGL and PYGB but is Irrelevant for ccRCC Cell
Growth, Despite Glycolytic Entry of Glycogen-Derived Glucose
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The data showing that glycogen depletion does not affect in vitro ccRCC cell
proliferation were rather unexpected, since it had been shown that GYS1 inhibition
reduces cell proliferation of other types of cancer, such as leukemia (Bhanot et al,
2015)222. An alternative hypothesis to explain this apparent lack of phenotype upon
GYS1 inhibition in ccRCC cells proposes that increased GYS1 expression and glycogen
accumulation is a collateral effect of HIF-1α activation and other factors, simply making
glycogen generation a byproduct. Cells may need to simultaneously increase activity of
the breakdown pathway to maintain glycogen homeostasis and avoid aberrant glucose
storage into glycogen. Therefore, pVHL-deficient ccRCC cells may require enzymes
involved in glycogen breakdown to balance enhanced GYS1 activity for metabolic
homeostasis.
To investigate this further, glycogen catabolism (glycogenolysis) was functionally
examined in ccRCC (Fig. 3.3a; pg. 95). Glycogen phosphorylase is the rate-limiting
enzyme for glycogen degradation and comprises three isoforms in mammals: liver
(PYGL), muscle (PYGM), and brain (PYGB) 216. As shown in Figure 3.1e, both PYGL and
PYGM mRNA abundance were elevated in ccRCC. Since PYGM expression at baseline
was much lower than PYGL, PYGL was initially evaluated. Similar to GYS1, PYGL
mRNA levels were amplified in all tumor stages (Fig. 3.3b; pg. 95). To genetically block
glycogenolysis, two independent sgRNAs were pooled to target PYGL, producing a
nearly complete loss of PYGL protein (Extended Data Fig. 3.4a, b; pg. 96). Because
glycogen was depleted in vitro within 12 hours following glucose deprivation (Extended
Data Fig. 3.4c; pg. 96), glycogen levels were measured at 6 hours in glucose-free
medium. This time point allows cells to engage glycogenolysis without complete
depletion before glycogen could be harvested. PYGL KO was unable to protect glycogen
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from degradation during this time frame (Extended Data Fig. 3.4d; pg. 96), suggesting
that these cells either did not utilize PYGL to mobilize glycogen under glucose deprived
conditions or there exists redundancy in this process. Consistent with our finding, Favaro
et al.184 showed that in a GBM cell line U87, PYGL knockdown did not increase glycogen
content under normoxia. However, they obtained the opposite result under hypoxia,
where glycogen accumulated and proliferation decreased in shPYGL cells. To examine
whether this can be recapitulated in ccRCC cells, PYGL WT/KO cells were subjected to
hypoxia treatment (0.5% O2). In contrast to U87 cells, PYGL depletion in ccRCC cells did
not accumulate more glycogen under hypoxia (Extended Data Fig. 3.4e; pg. 96). In
addition, there was no difference in cell growth between WT and PYGL KO cells when
cultured in any condition tested (replete, low serum, low glucose, low oxygen)
(Extended Data Fig. 3.4f; pg. 96). Taken together, these data suggest that although
PYGL expression is upregulated in ccRCC, it is not necessary for glycogenolysis, nor it
is required for in vitro cell growth.
As PYGL was insufficient to control glycogen breakdown, other isoforms were
analyzed for functional redundancy. Although PYGB expression was downregulated in
ccRCC tumors, it had comparable baseline mRNA levels as PYGL (Fig. 3.1e; pg. 90).
Neither genetic knockout or constitutive overexpression of PYGB protein disrupted
proliferation of UMRC2 under metabolic stress conditions (Extended Data Fig. 3.4g, h;
pg. 96). Upon reduction of PYGB protein, PYGL protein levels were increased,
suggesting possible compensation (Extended Data Fig. 3.4g; pg. 96). Consistent with
TCGA patient data, PYGM mRNA abundance was very low compared to the other two
isoforms in UMRC2 (Extended Data Fig. 3.4i; pg. 96), and PYGM was not evaluated
further. Therefore, PYGL and PYGB were simultaneously depleted with sgRNAs to avoid
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compensation from either enzyme (Fig. 3.3c, Extended Data Fig. 3.5a; pgs. 95 and
97). Notably, PYGB/L DKO completely prevented glycogenolysis under glucose
deprivation, suggesting both these isoforms are active in ccRCC (Fig. 3.3d, Extended
Data Fig. 3.5b; pgs. 95 and 97). However, PYGB/L DKO cells did not exhibit higher
glycogen content than WT cells under hypoxia, despite a trend towards increased
deposition of glycogen with low oxygen exposure (Extended Data Fig. 3.5c; pg. 97).
This result suggests that ccRCC cells do not use any glycogen-derived glucose under
hypoxic conditions, perhaps due to the increased uptake of extracellular glucose
downstream of even greater hypoxia-mediated HIF stabilization. In addition, PYGB/L
DKO did not affect cell proliferation under any conditions (Fig. 3.3e, Extended Data Fig.
3.5d; pgs. 95 and 97). To verify this result independently, a selective glycogen
phosphorylase inhibitor, GPi, was employed. GPi dose-dependently maintained
glycogen content in glucose-free culture condition (Fig. 3.3f, Extended Data Fig. 3.5e;
pgs. 95 and 97), and during a long-term treatment, GPi blocked glycogen degradation
when cells were cultured in low glucose (2mM) or no glucose (0mM) conditions,
regardless of oxygenation (Fig. 3.3g, Extended Data Fig. 3.5f; pgs. 95 and 97).
Consistent with PYGB/L DKO, GPi treatment did not affect in vitro ccRCC cell growth
(Fig. 3.3h, Extended Data Fig. 3.5g; pgs. 95 and 97). These findings indicate that
ccRCC tumor cells do not rely on glycogen breakdown for growth.
Despite no observable role in maintaining ccRCC viability, glycogen is rapidly broken
down under low glucose conditions (Extended Data Fig. 3.4c; pg. 96), suggesting that
glycogen-derived glucose is metabolized in some way. Therefore, glycogen was labeled
with [U-13C] glucose and then either allowed to or prevented from breakdown to
specifically determine how glycogen-derived glucose was utilized (Fig. 3.3i, and
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Extended Data Fig. 3.6a, b; pgs. 95 and 98). As a proof of principle, the percentage of
intracellular, labeled glucose relative to unlabeled glucose was greater in cells that can
properly catabolize glycogen under low glucose conditions (Extended Data Fig. 3.6c;
pg. 98). Mass spectrometry results indicated that glycogen-derived glucose was
diffusely processed into various metabolites (Extended Data Fig. 3.6d; pg. 98), but
perhaps more concentrated in glycolytic intermediates and serine rather than the TCA
cycle (Fig. 3.3i, Extended Data Fig. 3.6d; pgs. 95 and 98).
Due to increased glyceraldehyde-3-phosphate (G3P), serine/glycine, and very
slightly ribose-5-phosphate labeling, additional experiments were designed to test
potential proliferation defects in cells that lack glycogenolysis under nutrient conditions
pertaining to these metabolites. Aside from the obvious role of G3P in glycolysis, G3P
can also be catalyzed to generate glycerol, which is necessary for lipid synthesis.
Serine/glycine and the pentose phosphate pathways both produce NAPDH, also needed
for lipid synthesis. Therefore, UMRC2 control or PYGB/L DKO cells were subjected to
lipid starvation and assessed for relative cell numbers over 7 days. Although UMRC2
cells typically grow poorly without an exogenous source of lipids, this was exacerbated
somewhat in cells that cannot break down glycogen (Fig. 3.3j; pg. 95) (see below for
further discussion).
To evaluate whether these metabolic perturbations could also affect other cellular
functions aside from growth, such as migration, Boyden chamber assays were
performed using control or PYGB/L DKO UMRC2 cells. Similar to the lack of a
proliferation phenotype, no observable change in migration was detected between cells
that can or cannot engage in glycogenolysis (Extended Data Fig. 3.7a, b; pg. 99).
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Glycogen Metabolism has No Substantial Role in Tumor Progression of ccRCC
Xenograft Models
Lastly, to determine whether glycogen metabolism is important for ccRCC tumor
progression in vivo, we systematically transplanted our UMRC2 models into both flanks
of nude mice. For glycogen synthesis, no significant difference was evident between the
growth of GYS1 KO and WT tumors (Fig. 3.4a; pg. 100), despite robust glycogen and
GYS1 protein depletion (Fig. 3.4b, c; pg. 100). Similarly, for glycogen breakdown, no
consistent statistically significant effects on tumor volume or weight were observed when
both PYGL and PYGB were effectively eliminated, and glycogen levels were either
maintained or slightly elevated in PYGB/L DKO tumors (Fig. 3.4d-f; pg. 100).
Collectively, these results indicate that neither glycogen accumulation nor homeostasis
plays a major role in ccRCC tumor models.

3.4 Discussion
In this study, we demonstrated that glycogen is largely unnecessary for ccRCC cell
growth in a variety of models and stress conditions, clarifying an important clinical
distinction for a classical biological feature of the disease. Only under low oxygen and
low lipid conditions did inhibition of glycogen breakdown appear to modestly reduce cell
growth. One explanation for this phenotype could be that ccRCC cells metabolize
glycogen-derived glucose in pathways important for lipid synthesis, which is why no
phenotype was observed in lipid replete culture conditions. It remains perplexing why
25mM exogenous glucose could not compensate for the lack of glycogen-derived
glucose during lipid starvation. Nevertheless, since this phenotype was not observed in
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transplantable in vivo models, it is likely that overall deregulated glycogen metabolism in
ccRCC is a side effect of constitutive HIF-1α signaling with minimal biological importance
under conventional stress conditions (i.e. low glucose, low oxygen). In other cancer
types, such as GBM11 and NSCLC12, data does exist supporting a pro-tumorigenic role
of glycogen. Whether these tumor microenvironments have reduced fatty acid or
triglyceride availability is unknown. Therefore, a key unanswered question remains in
how cancer cells of distinct metabolic dependencies and microenvironments utilize
glycogen. In our ccRCC models, we reproducibly observe glycogen degradation in low
glucose and, conversely, glycogen retention in PYGB/L DKO cells exposed to glucose
deprivation. This indicates ccRCC cells mobilize glycogen-derived glucose for some
metabolic processes. Based on the glycogen labeling experiment, potential metabolic
pathways include glycolysis, serine/glycine biosynthesis, and the pentose phosphate
pathway. More in depth metabolite analyses, such as antioxidant readouts or lipidomics,
could clarify and connect a metabolic role of glycogen to a specific stress condition. In
vivo models of PYGB/L DKO tumor growth in either a low- or high-fat diet to mimic
changes in serum lipids, or with antiangiogenic treatment to intensify a hypoxic tumor
microenvironment, could also be examined.
Future work on glycogen in ccRCC could identify distinct destinations of glycogenderived glucose under specific culture conditions. This may reveal synthetic lethality
approaches between GYS1 or PYGB/L inhibition, tailored to a patient’s unique tumor
metabolism. For example, tumors addicted to glutamine, fatty acid, or acetate availability
may become vulnerable when glycogen cannot feed glucose-1-phosphate into the
central carbon pathway (Varnier et al, 1995; Lundsgaard et al, 2018; Hardin et al,
1997)223-225. Additionally, it has recently been described that glycogen breakdown in the
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nucleus can regulate gene expression through altering histone acetylation in non-small
cell lung cancer185. Whether or not nuclear glycogen impacts the epigenetic landscape,
or if the epigenetic profile itself can alleviate any proliferation defects from the loss of
glycogen metabolism in ccRCC, has yet to be explored. Another avenue of synthetic
lethality could be in serine/glycine biosynthesis (Extended Data Fig. 3.6d; pg. 97).
Nevertheless, we suggest that elevated glycogen content in ccRCC patient tumors
should not be considered a therapeutic target on its own.
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Figure 3.1. Glycogen synthesis and breakdown are hyperactive in ccRCC tumors. a. Schematic representation of
glycogen synthesis and breakdown pathway in the cytosol. Briefly, glucose conversion into glucose-1-phopshate (G1P) is
added or subtracted from oligosaccharide chains scaffolded by the core protein, glycogenin. Green hexagon: singly added
glucose-1-phosphate; Pink hexagon: polysaccharide molecules added; Blue hexagon: units added as new branch. b.
Upper panel: Glycogen extracted from 20 pairs of fresh frozen ccRCC patient tumors and adjacent normal kidneys and
then quantified using glycogen assay kit (see Methods). Lower panels: Summary of tumors analyzed for glycogen levels,
and subdivided according to tumor stage; n=20 biologically independent human ccRCC tumor/normal paired samples.
Box plots (min. to max. all points): center=median, bounds=25th and 75th percentiles, whiskers=min. and max. values. c.
Abundance of glycogen metabolism related metabolites in same human ccRCC tumor/normal paired samples. Data
presented as mean +/- SEM. d, e. Normalized RNA-seq reads of glycogen synthesis genes (PGM1, UGP2, GYS1, and
GBE1) and glycogen breakdown genes (PYGL, PYGB, PYGM, and AGL) in ccRCC (n=428) and normal kidney (n=66)
samples; n denotes biologically independent human tissue samples. RNA-seq data obtained from TCGA. Box plots (min.
to max. all points): center=median, bounds=25 th and 75th percentiles, whiskers=5th and 95th percentiles. P values
determined by two-tailed Student’s t test. GLUT: glucose transporter; HK: hexokinase; PPP: pentose phosphate pathway
PGM: phosphoglucomutase; UGP: UDP-glucose pyrophosphatase; UDP-glucose: uridine diphospho-glucose; GYS:
glycogen synthase; GBE: glycogen branching enzyme; PYGL/M/B: glycogen phosphorylase, liver/muscle/brain; DBE
(encoded by AGL): debranching enzyme. Red denotes gene expression increase.
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Extended Data Figure 3.1 (related to Figure 3.1). Glycogen synthesis and breakdown are hyperactive in ccRCC
tumors. a. Glycogen quantification of six ccRCC cell lines in replete conditions (10% FBS, 25mM glucose DMEM)
normalized to protein mass; n=3 technical replicates as an example of reproducible experiments. Data presented as mean
+/- SD. “H2”: cell lines exclusively expressing HIF-2α. “H1H2”: cell lines expressing both HIF-1α and HIF-2α. b.
Abundance of glycogen metabolism-related metabolites (glucose-1-phosphate, maltose, maltotriose, and maltotetraose)
in n=138 biologically independent human ccRCC tumor/normal paired samples; data extracted from Hakimi AA, et al 16.
Data presented as mean +/- SEM. c. qRT-PCR of GYS1, PYGB, PYGL, and PYGM in 20 matched ccRCC and adjacent
normal kidney tissues; n=3 technical replicates per tissue sample as an example of reproducible experiments. Data
presented as mean +/- SD. Ribosomal subunit 45S RNA (45S) utilized as the endogenous control gene. P values
determined by two-tailed Student’s t test.
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Figure 3.2. Elevated glycogen synthesis enzyme, GYS1, in ccRCC tumors does not affect proliferation in vitro. a.
Schematic model of simplified glycogen metabolism pathway and hypothetical effect of GYS1 blockade on glycogen and
free glucose. b. Normalized RNA-seq reads of GYS1 in stage-stratified ccRCC (n=428) and normal kidney (n=66)
samples; n denotes biologically independent human tissue samples. RNA-seq data obtained from TCGA. Box plots (min.
to max. all points): center=median, bounds=25 th and 75th percentiles, whiskers=5th and 95th percentiles. Center
line=median. c. qRT-PCR (left) and immunoblots (right) of GYS1 in matched ccRCC and normal kidney samples; n=20
biologically independent human ccRCC tumor/normal paired samples. For qRT-PCR, TBP and ACTB utilized as
endogenous control genes. Relative mRNA expression determined by normalizing to expression in normal tissues. d.
UMRC2 ccRCC cells transduced with two independent sgRNAs against GYS1 (sg1 and sg3) or a control sgRNA (sgC).
Western blot analysis performed 7 days after virus infection to assess GYS1 expression. e. Glycogen content measured
in cells described in d on day 14 after virus infection; n=3 technical replicates as an example of reproducible experiments.
Data presented as mean +/- SD. Relative glycogen amount determined by normalizing to glycogen level in sgC cells. f.
Growth curves for cells described in d cultured in medium containing 1% FBS combined with indicated glucose and
oxygen concentrations; n=6 biologically independent cell populations. Data presented as mean +/- SEM. Relative
absorbance determined by normalizing to values at Day 0. g. Representative images acquired at 40X magnification and
relative volumes of spheroids formed by cells described in d after 19 days culture; n=24 biologically independent
spheroids. Data presented as mean +/- SEM. Relative volume determined by normalizing to that of sgC spheroids.
Numbers denote average relative volumes. P values determined by two-tailed Student’s t test. For panels f and g, data
are presented as mean values +/- SEM.
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Extended Data Figure 3.2 (related to Figure 3.2). Glycogen synthesis enzyme GYS1 is overrepresented in ccRCC
and regulated by HIF-1α. a. UMRC2 and RCC4 (H1H2) ccRCC cells transduced with two independent shRNAs against
HIF1A (shHIF1A_52 and shHIF1A_9), EPAS1 (shHIF2A_6 and shHIF2A_7), or a SCR (scrambled shRNA) control. qRTPCR and Western blot for GYS1 shown. PDK1 and CCND1 included as positive controls for HIF-1α and HIF-2α
suppression, respectively. For qRT-PCR, TBP and ACTB utilized as endogenous control genes, and relative mRNA
expression determined by normalizing to expression in SCR samples; n=3 technical replicates as an example of
reproducible experiments. Data are presented as mean +/- SD. b. Glycogen quantification in UMRC2 cells transduced
with indicated shRNAs after 4 days; n=3 technical replicates as an example of reproducible experiments. Data are
presented as mean +/- SD. Relative glycogen amount determined by normalizing to levels in SCR samples. c. (Left panel)
EPAS1 (HIF-2A) depleted by two independent shRNAs (shHIF2A_6 and shHIF2A_7) or (right panel) ectopic VHL
expression in 786-O (H2) ccRCC cells. Expression relative to ACTB shown by qRT-PCR; n=3 technical replicates as an
example of reproducible experiments. Data are presented as mean +/- SD. d. Schematic representation of GYS regulation
by PP1 and PPP1R3 (see text for details). e. Normalized RNA-seq reads of PPP1R3B and PPP1R3C in stage-stratified
ccRCC (n=428) and normal kidney (n=66) samples; n denotes biologically independent human tissue samples. RNA-seq
data obtained from TCGA. Box plots (min. to max. all points): center=median, bounds=25 th and 75th percentiles,
whiskers=5th and 95th percentiles. P values determined by two-tailed Student’s t test.
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Extended Data Figure 3.3 (related to Figure 3.2). Glycogen is dispensable for ccRCC cell growth in vitro. a. RCC4,
UOK101, and 786-O ccRCC cells transduced with two independent sgRNAs against GYS1 (sg1 and sg3) or a control
sgRNA (sgC). Western blot analysis performed 7 days after virus infection to assess GYS1 expression. b. Glycogen
levels measured in cells described in a on day 7 after virus infection; n=3 technical replicates as an example of
reproducible experiments. Data presented as mean +/- SD. Relative glycogen amount was determined by normalizing to
glycogen level in sgC cells. c. Representative images acquired at 40X magnification and relative volumes of spheroids
formed by 786-O cells described in a after 19 days culture; n=24 biologically independent spheroids. Data presented as
mean +/- SEM. Relative volume was determined by normalizing to that of sgC spheroids. Numbers denote average
relative volumes. d. Growth curves for cells described in a cultured in medium containing 1% FBS combined with
indicated glucose and oxygen concentrations; n=6 biologically independent cell populations. Data presented as mean +/SEM. Relative absorbance was determined by normalizing to values at Day 0.
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Figure 3.3. ccRCC tumor cells do not rely on glycogen breakdown for growth in vitro despite glycolytic entry of
glycogen-derived glucose. a. Hypothetical effect of PYGL/M/B blockade on glycogen breakdown. b. Normalized TCGA
RNA-seq reads of PYGL in stage-stratified ccRCC (n=428 tumors) and normal kidney (n=66 tissue) samples. P values
determined by two-tailed Student’s t test. c. Protein assessment comparing WT UMRC2 cells and PYGL KO UMRC2 cells
described in Extended Data Figure 4b transduced with a control sgRNA against LacZ (sgC) or combined two sgRNAs
targeting PYGB (sgPYGB/L), respectively. SE, short exposure; LE, long exposure. d. Glycogen quantification of cells
described in c cultured in 25mM or 0mM glucose for 6 hours. Normalized to sgC in 25mM glucose. e. Growth curves for
cells described in c cultured in indicated conditions; n=6. Normalized to Day 0. f. Glycogen quantification of UMRC2 cells
cultured in 25mM (blue) or 0mM (red) glucose, treated with indicated concentrations of DMSO or GPi for 6 hours.
Normalized to 25mM glucose. g. Glycogen quantification of UMRC2 cells cultured in 25mM, 2mM, or 0mM glucose and
treated with DMSO (blue) or 5μM GPi (red) in 21% O 2 for 48 hours. Normalized to 25mM glucose condition plus DMSO. h.
Growth curves for UMRC2 parental cells treated with DMSO, 2.5μM, or 5μM GPi and cultured in indicated conditions; n=6
biologically independent cell populations. Normalized to Day 0. i. Upper panel: schematic of uniformly 13C-labeled ([U13
C]) glucose release from glycogen. Bottom panel: fold change in atomic percent excess (APE) of key glycolytic
metabolites. Normalized to 0 hr; n=3. G3P+3: Glyceraldehyde-3-phosphate with three 13C carbons. LAC+3: Lactate with
three 13C carbons. GPi concentration was 10μM (bottom panel). j. Growth curves for UMRC2 under the indicated culture
conditions; n=3 biologically independent cell populations. For I and J, two-way ANOVA with Sidak’s multiple comparison
test was used to determine significance. For all glycogen measurements, data from n=3 technical replicates and
presented as mean +/- SD. For all growth curves, data from biologically independent cell populations and presented as
mean +/- SEM.
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Extended Data Figure 3.4 (related to Figure 3.3). PYGL is not required for glycogen breakdown and in vitro ccRCC
cell growth. a, b. Protein assessment of 786-O and UMRC2 ccRCC cells transduced with three independent or two
pooled sgRNAs against PYGL (sg1, sg3, sg4, or sg3+4) or a control sgRNA (sgC). Samples collected at 7 (a) or 6,8 (b)
days after lentiviral infection. c. UMRC2 cells cultured in glucose-free medium for indicated time points, glycogen
extracted and quantified. Relative glycogen amount determined by normalizing to glycogen level in cells at 0 hour. c. Cells
described in b cultured in medium with 25mM glucose or starved in glucose-free medium for 6 hours, glycogen extracted
and quantified. Relative glycogen amount determined by normalizing to glycogen level in sgC cells cultured in medium
with 25mM glucose. e. Cells described in b cultured in 0.5% O2 for indicated time points, glycogen extracted and
quantified. Relative glycogen amount determined by normalizing to glycogen level in sgC cells cultured in 21% O 2. f.
Growth curves for cells described in b cultured in indicated conditions; n=6 biologically independent cell populations.
Relative absorbance determined by normalizing to values at Day 0. g. Protein assessment of pooled sgRNAs 1+4
targeting PYGB (sgPYGB) or overexpression of PYGB (PYGB OE), upper and bottom panels respectively. sgC: control
(guide targeting LacZ); sgPYGB/L: double knockout. h. Growth assays of UMRC2 under the indicated conditions. Live cell
numbers were measured by Trypan Blue exclusion, and finalized values adjusted for dilution; n=3 biologically
independent cell populations. PYGB knockout and PYGB overexpression (upper and bottom panels respectively).
Parental refers to uninfected UMRC2 cells. I. qRT-PCR on UMRC2 cells for glycogen phosphorylase isoforms; n=3
technical replicates. Data presented as mean +/-SD. Ribosomal subunit 45S RNA (45S) utilized as the endogenous
control gene. For all glycogen measurements, data from n=3 technical replicates and presented as mean +/- SD. For all
growth curves, data are presented as mean +/- SEM.
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Extended Data Figure 3.5 (related to Figure 3.3). ccRCC tumor cells do not rely on glycogen breakdown for growth.
a. WT and PYGL KO 786-O cells transduced with a control sgRNA against LacZ (sgC) or combined two sgRNAs targeting
PYGB (sgPYGB/L), respectively. Top 50% GFP positive cells sorted for culture. Western blot analysis performed 14 days
after virus infection to assess PYGL and PYGB expression. SE, short exposure; LE, long exposure. b. Cells described in
a cultured in medium with 25mM glucose or starved in glucose-free medium for 6 hours, glycogen extracted and
quantified. Relative glycogen amount determined by normalizing to glycogen level in sgC cells cultured in medium with
25mM glucose. c. UMRC2 and 786-O sgC vs. sgPYGL/B ccRCC cells cultured in 0.5% O 2 for indicated time points,
glycogen extracted and quantified. Relative glycogen amount determined by normalizing to glycogen level in sgC cells
cultured in 21% O2. d. Growth curves for UMRC2 cells described in Figure 3c and 786-O cells described in a cultured in
indicated conditions. Relative absorbance determined by normalizing to values at Day 0. e. 786-O cells cultured in
medium with 25mM or 0mM glucose, treated with indicated concentrations of DMSO or GPi for 6 hours. Glycogen
extracted and quantified. Relative glycogen amount determined by normalizing to glycogen level in cells cultured in 25mM
glucose condition. f. UMRC2 and 786-O cells cultured in medium with 25mM, 2mM, or 0mM glucose, treated with DMSO
or 10μM GPi in 21% O2 or 0.5% O2 for 48 hours. Glycogen extracted and quantified. Relative glycogen amount
determined by normalizing to glycogen level in cells cultured in 25mM glucose condition treated with DMSO. g. Growth
curves for UMRC2 and 786-O parental cells treated with DMSO, 5μM, or 10μM GPi and cultured in indicated conditions.
Relative absorbance determined by normalizing to values at Day 0. For all glycogen measurements, data from n=3
technical replicates and presented as mean +/- SD. For all growth curves, data from n=6 biologically independent cell
populations and presented as mean +/- SEM.

97

Extended Data Figure 3.6 (related to Figure 3.3). Glycogen-derived glucose broadly enters the central carbon
pathway during glucose starvation. a. Glycogen labeling experimental design. [U-13C]: uniformly labeled heavy carbon
(13C); GPi: glycogen phosphorylase inhibitor. Small blue or red circles denote free, unlabeled or labeled glucose,
respectively. Large blue or red undefined shapes denote unlabeled or labeled glycogen, respectively. b. Sample collection
scheme for metabolomic analysis following labeled glycogen breakdown or retention. c. Percentage of labeled glucose
(Glucose M+6) relative to unlabeled glucose in cells over 6 hours of glycogen breakdown or retention; n=3 biologically
independent cell populations. d. Fold change in APE relative to time 0 for indicated metabolites after 3 hours (upper
panel) and 6 hours (bottom panel) of glycogen breakdown or retention; n=3 biologically independent cell populations. For
all metabolite measurements, data presented as mean +/- SEM. CIT: citrate; SUCC: succinate; FUM: fumarate; MAL:
malate; ASP: aspartate; GLU: glutamate; ALA: alanine; GLY: glycine; SER: serine; R5P: ribose-5-phosphate. ND: not
detectable. (+1,2,3 denotes number of 13C carbons). Two-way ANOVA with Sidak’s multiple comparison test was used to
determine significance.
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Extended Data Figure 3.7 (related to Figure 3.3). Glycogen availability does not alter cell migration. a. Representative
field image of crystal violet-stained UMRC2 cells under the specified conditions and genetic alterations. Scale bar=200μm.
b. Quantification of cell migration calculated as average cell number per field; n=3 biologically independent cell
populations (average count of 4 center-oriented fields per sample). Data presented as mean +/- SEM. sgC: UMRC2
control sgLacZ; sgPYGB/L: UMRC2 PYGB/L double knockout. Two-way ANOVA with Sidak’s multiple comparison test
was used to determine significance.
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Figure 3.4. Genetic perturbation in glycogen metabolism does not alter ccRCC xenograft progression in vivo. a.
Tumor volume measurements for UMRC2 control (sgC) and GYS1 KO (sg1) subcutaneous xenograft tumors (in opposing
flanks of each animal) at indicated time points (left); n=7 biologically independent tumors. Tumor weights at harvest
determined (right). Note: some points overlap. b. Glycogen quantification of 7 pairs of sgC and sg1 xenograft tumors at
harvest; n=3 technical replicates per tumor sample. Relative glycogen amount determined by normalizing to glycogen
level in #1 sgC tumor. c. Western blot analysis for GYS1 in xenograft tumors. d. Tumor volume measurements for
UMRC2 control (sgC) and PYGL/B KO (sgPYGL/B) subcutaneous xenograft tumors (in opposing flanks of each animal) at
indicated time points (left); n=10 biologically independent tumors. Tumor weights at harvest determined (right). Note:
some points overlap. e. Glycogen quantification of 10 pairs of sgC and sgPYGL/B xenograft tumors at harvest; n=2
technical replicates per tumor sample. Relative glycogen amount determined by normalizing to glycogen level in #1 sgC
tumor. f. Western blot analysis for PYGL and PYGB protein in xenograft tumors. sgC: UMRC2 control sgLacZ; sgP:
UMRC2 sgPYGB/L. For tumor volume and weight measurements, two-way ANOVA with Sidak’s multiple comparison test
and paired t test were used to determine significance, respectively. For all glycogen measurements, data are presented
as mean +/- SD.
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CHAPTER 4: Conclusions and Future Directions

This final chapter will summarize and critically assess the pertinent results described in
the previous two chapters. I hope to convey an honest interpretation of the data
juxtaposed to propositions of new experimentation that will deepen our scientific
understanding whilst outlining a practical path forward for clinical progress. Lastly, I will
aim to connect our findings and my perspective with the broader field of glucose
metabolism in cancer, as discussed in the introduction, to provide a navigational
blueprint for the future of translational research in liver and kidney cancer.
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4.1 Overall Summary: Return to the Role of Glucose Metabolism in Cancer
Glucose utilization provides cancer and cancer-associated cells in the local milieu
with the energy, metabolite derivatives, and antioxidant balance to drive tumor
progression. Thus, understanding precisely how glucose is catabolized in cancer relative
to normal tissue is an attractive targeted therapy. Historically, the initial wave of targeted
therapies was developed against various mitogenic kinases harboring oncogenic
mutations, namely: Imatinib inhibition of Bcr-Abl in chronic myelogenous leukemia
(O’Brien et al, 2003)226, Vemurafenib inhibition of BRAF in melanoma (Chapman et al,
2011)227, and Crizotinib inhibition of ALK in non-small cell lung cancer (Shaw et al,
2013)228. However, many patient tumors possess de novo or acquired resistance
through secondary mutations or activation of parallel pathways, which has directed the
field towards identifying next-generation drugs and combination strategies (Aldea et al,
2021)229.
Ultimately, sustained growth signaling or avoidance of cell death mechanisms,
intrinsically- or immunologically-mediated, are major obstacles to the future of targeted
therapy. This is further compounded by the substantial genetic and transcriptomic
heterogeneity between patients, primary and metastatic sites within a single patient, or
clonally within an individual tumor (Dagogo-Jack and Shaw, 2017)230. Therefore, in an
effort to develop novel cancer treatments with greater efficacy across a general
population, drug discovery and translational research is currently investigating role of
metabolism in tumors: a complex yet fundamental network of biochemical processes that
integrate oncogenic drivers with nutrient availability. In particular, the central carbon
pathway, which as its nomenclature suggests is principal for all components of cellular
metabolism, provides numerous catabolic fates of glucose and dictates cell survival.
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Specifically, our work focused on aspects of glucagon-regulated glucose metabolism
in liver and kidney cancer, gluconeogenesis and glycogenolysis, respectively. From
these studies, we identified two main conclusions: (1) glucagon signaling can be
experimentally manipulated to antagonize HCC, through an unknown mechanism
independent of gluconeogenic gene expression; and (2) glycogenolysis is not required
for ccRCC progression but may contribute to cell viability under specific lipid and oxygen
stress conditions. These data represent interesting cases of metabolic vulnerabilities in
cancer that can and should be further explored within a precise framework. Similar to the
importance of biomarker distinction and patient stratification in clinical trials (Goossens
et al, 2015)231, prioritizing future experiments is necessary to optimize both scientific and
medical benefits. I advise that direct continuation of both projects is not currently justified
by the data; however, incorporating glucagon, gluconeogenesis, and glycogen
metabolism into the context of tumor microenvironment or clinical research may yield
more promising results for glucagon treatments or inhibitors of glycogen breakdown in
liver or kidney cancer, respectively.

4.2 Criticisms and Future Directions
Glucagon/GCGR in Hepatocellular Carcinoma
To summarize our research into glucagon and GCGR in hepatocellular carcinoma,
we report 5 major findings: (1) liver cancer cells are robustly dependent on exogenous
glucose for growth; (2) the glucagon receptor, GCGR, is downregulated at the mRNA
level in both patient liver tumors and cell line models; (3) supraphysiologic levels of
GCGR can re-sensitize SNU398 cells to glucagon treatment by enhancing cAMP
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production, PKA activity, and nuclear CREB phosphorylation; (4) neither
glucagon/GCGR nor epigenetic inhibitors are sufficient to completely restore
gluconeogenic gene expression to that of primary human hepatocytes; and (5) SNU398
cells over-expressing GCGR uniquely, but reproducibly, display reduced viability upon
glucagon treatment that appears to be independent of CREB and gluconeogenic gene
expression. These results were obtained over the course of 2 years and address an, as
of yet, uncharacterized area of hormone-dependent glucose metabolism in cancer.
My critical assessment of the data is mainly that glucagon signaling is not a reliable
tumor suppressor pathway. Supporting this interpretation, only one cell line showed a
consistent phenotype of increased cell death and decreased cell proliferation. Moreover,
this isolated effect was only observed at a non-physiological setting with 100-fold
overexpression of GCGR in SNU398 relative to normal human hepatocytes. No parental
cell line was affected by glucagon exposure in any measurable way. Additionally, we
examined whether glucagon could reduce SNU398 GCGR tumor progression in a
xenograft model, but measured no significant difference in tumor volume (data not
shown). GCGR tumor volumes and weights were actually larger on average compared
to eGFP controls, which was unexpected given that they grow at equivalent rates in
vitro.
Technical errors aside, it is concerning that the glucagon/GCGR phenotype in vitro
failed to translate in vivo, a closer proxy to the human patient. Discrepancies in glucagon
stability and concentration could provide an explanation; however, this was not
evaluated in sufficient detail to conclusively determine. If the in vitro phenotype was
robust, meaning a majority of cell lines displayed a similar reduction in proliferation with
glucagon treatment and GCGR overexpression, then I believe it would have been more
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reasonable to elucidate the precise in vivo conditions and pharmacodynamics of
glucagon. Of course, it is also plausible that a phenotype in other cell lines or in vivo
could have been created with combination strategies (i.e. glucagon/GCGR + Sorafenib)
or specific surgical procedures (i.e. transarterial chemoembolization with glucagon on
GCGR tumors). However, given the substantial amount of negative data, as well as an
undetermined mechanism for the phenotype in SNU398 GCGR cells, I believe further
study into glucagon signaling within cancer cells themselves is not an effective use of
time and resources.
However, I do strongly believe that glucagon signaling should be further
characterized in the context of liver cancer in two ways: (1) GCGR silencing in early
tumor initiation; and (2) the glucagon-induced effects of hyperglycemia in diabetic liver
cancer patients. In the next section, I will describe the rationale and potential
experimental design to support these research queries.
The cell-of-origin of most forms of primary liver cancer is hepatocytes and is
diagnosed as hepatocellular carcinoma (HCC); the other subtype being
cholangiocarcinoma of the hepatic bile duct. However, hepatocytes are effectively
categorized into metabolic zonations, depending on spatiotemporal factors within the
vascular architecture of the liver, such as differential oxygen gradients, as well as
expression of the Wnt/β-catenin pathway (Birchmeier, 2016; Droin et al, 2021; Manco
and Itzkovitz, 2021)232-234. In zone 1, hepatocytes are responsive to glucagon and
regulate blood glucose homeostasis, whereas zone 3 hepatocytes are dominated by
Wnt signaling and glycolysis.
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It would be interesting to determine whether GCGR-expressing zone 1 hepatocytes
are the cell-of-origin for specific etiologies of liver cancer, and if downregulation of
GCGR mRNA is an early event required for tumor initiation. To test this, lineage tracing
of both zone 3 (Axin2-CreERT2; Rosa26-Lox-Stop-Lox-tdTomato) (Kurosaki et al, 2021)235
and zone 1 (GCGR-FlpERT2; Rosa26-FRT-Stop-FRT-GFP) hepatocytes could specifically
label cells green that express GCGR and red that express Axin2 when treated with
tamoxifen. Then, mice can be assigned into various cohorts of liver tumorigenesis
models, particularly those that reflect the rising incidences of hepatic steatosis (Anstee
et al, 2019)236, and monitored for tumor development. Upon dissection, if more green
tumors are observed than red, indicating a predominance of zone 1-derived
hepatocytes, then we could conclude that GCGR-expressing cells may directly undergo
neoplastic transformations. Finally, qPCR can be performed to quantify the relative
expression of GCGR in these green tumors, hypothesized to be decreased relative to
pre-tumorigenesis. In this regard, biopsies of at-risk patients could be monitored for
GCGR mRNA by fluorescent in situ hybridization over time.
Further validation would address whether GCGR add back, potentially by
hydrodynamic DNA injection, could restore glucagon signaling and gluconeogenesis to
slow or revert early tumor onset. As liver cancer prevention and imaging becomes more
refined, the efficacy of additional hormones, such as glucagon, and pharmacological
agents, such as epigenetic inhibitors, could be evaluated. From these hypothetical
experiments and their results, we could provisionally conclude that certain risk factors
are associated with zone 1 liver cancer, a subsequent repression of GCGR, and that
stabilizing glucagon signaling with or without other therapeutics could contribute to
reducing HCC burden.
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Another avenue of research pertaining to glucagon signaling is in cell nonautonomous crosstalk between glucagon-responsive, normal hepatocytes and liver
cancer cells. Type II diabetes is a major risk for HCC development, and hyperglycemia is
at least partially maintained by excessive glucagon activity and gluconeogenic output.
Therefore, in liver cancer patients with diabetes, does elevated glucagon signaling
promote tumor progression by sustaining high levels of circulating or local glucose? I
believe this is critical to understand because in this sense glucagon signaling would be
oncogenic rather than tumor suppressive. Moreover, it is feasible that antagonists of
GCGR, currently under investigation for diabetes, could then be readily utilized for
hyperglycemic liver cancer patients.
To test this, liver tumors could be generated in obesity-induced, insulin-resistance
mouse models of type II diabetes (Lepdb) (Luo et al, 2020)237. Then, one cohort would
receive the phase I-tested, monoclonal anti-GCGR antibody, REGN1193 (Okamoto et al,
2017; Kostic et al, 2017)238,239, and the other cohort administered saline as a control. At
endpoint, tumor parameters would be quantified, as well as plasma and intratumoral
glucose concentrations. I hypothesize that REGN1193 would decrease tumor volume
and positively correlate with reduced glucose levels, both systemically and within the
tumor. For a mechanistic validation, Lepdb mice could be crossed to a strain that harbors
a constitutively expressed G6PC gene (Rosa26-G6PC)(Landau et al, 2016)240. These
Lepdb; Rosa26-G6PC mice would hypothetically display enhanced G6PC-mediated
glucose export independent of GCGR activity. Following the same tumorigenesis
protocol, if tumor reduction by REGN1193 is indeed due to dampened gluconeogenesis,
then mice with constitutive expression of the gluconeogenic enzyme G6PC could be
insensitive to treatment.
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Furthermore, experiments can be designed to test whether the glucose produced
from GCGR activity is specifically from normal hepatocytes. I predict this to be the case
because GCGR expression is decreased in liver cancer cells, as described previously,
and should not be capable of synthesizing new glucose directly. Rather, adjacent zone 1
hepatocytes within the tumor microenvironment could generate and export glucose
locally for uptake by tumor cells, as well as by tumor-associated cells, such as
macrophages or hepatic stellate cells.
To test this possibility, conditioned media experiments can be performed with purified
hepatocytes and cancer cells derived from the Lepdb diabetic tumor model. First,
hepatocytes can be incubated with

13

C-labeled pyruvate, a gluconeogenic carbon

source, and stimulated with glucagon to convert pyruvate to 13C-labeled glucose for 2448 hours to fully engage the gluconeogenic pathway. Then, the media from these cells,
hypothetically containing 13C-labeled glucose could be transferred to tumor cells without
any other source of glucose. I predict that this hepatocyte-originated labeled glucose
would be swiftly imported and catabolized in cancer cells. The same experiment could
be repeated with other tumor-associated cell types. While not an exact replica of the in
vivo setting, from these hypothetical data, I would conclude that it is technically plausible
for glucagon-responsive hepatocytes to directly feed local tumor cells.
Overall, these studies are important to consider, as they may optimize patient
delineation for clinical trials in diabetic vs. non-diabetic liver cancer. In addition, it would
shed light on our understanding of exactly which cells are turning cancerous, and how
GCGR and gluconeogenesis as a whole metabolic process regulate HCC progression.
Glycogenolysis in ccRCC
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Our work in glycogen metabolism in kidney cancer revealed 2 key pieces of data: (1)
neither glycogen deposition nor lysis is required for cell viability in vitro or in vivo, despite
its elevated abundance in tumor tissue; and (2) glycogen is rapidly depleted during
glucose starvation and contributes carbons to lactate, ribose-5-phosphate, and serine.
Although a few late experiments suggested that glycogenolysis may provide a protective
effect against simultaneous lipid and oxygen depletion, through unknown mechanisms,
the vast majority of the data supports a HIF-driven, inconsequential role of glycogen
accumulation in kidney cancer.
While my specific contribution to this project was minor and largely relegated to the
revisions and manuscript preparation, I can provide a brief discussion of future
translational research in renal carcinoma glycogen, and how our own results could serve
as a basis. Generally, I believe subsequent studies should focus on reactive oxygen
species (ROS) and non-metabolic functions of glycogen in ccRCC, rather than further
examining the role of glycogen with other nutrient stress conditions (i.e. not glucose,
oxygen, and lipid availability (what we have done)).
Glycogen metabolism, by definition, is a highly dynamic and fluid process. So far as I
know, glycogen has only been described as a storage mechanism for glucose,
especially under low oxygen. The prevention of glucose catabolism via glycogen
synthesis during temporary ischemia would hypothetically save glucose for maximal
energy production, through complete oxidation, once blood flow and nutrient availability
are restored. This is not unlike the metabolism of glycogen in skeletal muscle, whereby
glycogen is predominantly utilized for ATP generation by oxidative phosphorylation,
during higher intensity exercises between 1 minute and a few hours (Hargreaves and
Spriet, 2020)241. Additionally, since hypoxia is known to increase ROS (Chandel et al,
1998)242, glycogen storage and breakdown could also be coordinated with the pentose
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phosphate pathway to generate NADPH for antioxidant synthesis. Indeed, a recent
report studying the benefit of hypoxia responses in ischemic injury models showed that
Enarodustat, a compound that stabilizes hypoxia-inducible factors (HIFs), mitigated
kidney damage partially through elevated glycogen metabolism and antioxidant
synthesis (Ito et al, 2020)243.
While the precise relationship between mitochondrial ROS and glycogen processing
is unclear, I believe future experiments could examine the temporal role of glycogen
metabolism in the context oxidative stress, either in vitro or in physiologically-relevant
orthotopic models of kidney cancer and ischemia. In our glycogen tracing experiment,
we measured a slight increase in glycogen-derived ribose-5-P. However, we did not
assess ROS levels, which I hypothesize would likely have been increased in the cells
treated with a glycogenolysis inhibitor. In this regard, I believe it is worth preliminarily
testing whether glycogen metabolism could sustain viability during instances of oxidative
stress. A simple experiment could be to treat glycogenolysis-deficient (sgPYGL/B, see
Chapter 3) ccRCC cells with inhibitors of the electron transport chain, which are known
to leak electrons and create superoxide species if decoupled (Raimondi et al, 2020)244,
and measure ROS and cell viability levels. Further mechanistic experiments can utilize
exogenous antioxidants, such as N-acetyl-cysteine, to rescue the hypothesized
reduction in viability in the absence of glycogen breakdown.
It is possible that our subcutaneous xenograft tumor models did not experience
significant oxidative stress, and therefore may explain why glycogen metabolism
appeared to be dispensable. To stress the potential clinical advantages of studying
glycogen metabolism and ROS, multiple clinical trials are currently investigating the antiHIF2-α drug, Belzutifan (NCT04195750, NCT03634540, NCT04489771, NCT04626518,
NCT04586231, etc.), in advanced ccRCC. HIF inhibition is highly relevant to ROS, as
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previous work from our lab has demonstrated that HIF2-α siRNA increased the
abundance of ROS, particularly in combination with ionizing radiation (Bertout et al,
2009)245. Thus, if clinical HIF2-α antagonists leads to ROS accumulation, then glycogen
levels could functionally correlate to response rates and should be closely evaluated.
Lastly, a very novel, and perhaps antithetical, area of study is the potential nonmetabolic function of glycogen. Nuclear localization of glycogen synthetase (GYS) has
been reported in the absence of glycogen or when mutated, suggesting that glycogen
may also act as a somewhat cytosolic GYS-chelator (Cid et al, 2005; Diaz et al,
2011)246,247. This implies that glycogen could also bind and trap other proteins not
necessarily involved in its synthesis or catabolism. We also mentioned previously in
Chapter 3 that glycogen and its catabolic enzymes have been observed in the nucleus. It
would be extremely curious if glycogen, as a macromolecule, also possessed a
scaffolding or signaling role independent of its metabolism (hypothesized by one of the
co-first authors of Xie et al. 2021, Jun Song). As a pilot experiment, glycogen could be
purified, in a method similar to immunoprecipitation, and interacting proteins analyzed by
mass spectrometry. Protein identifications would then be queried for potential
involvement in signaling networks outside of strict glycogen metabolism. While this is
more basic research, if glycogen is found to interact with proteins that predict drug
response or patient outcome, pharmacological approaches targeting those interactions
could lead to new forms of therapies.
Additionally, in pondering recent reports of glycogen metabolism in immune cells,
including memory CD8+ T cells (Ma et al, 2018)248, antigen-presenting dendritic cells
(Thwe et al, 2017)249 innate neutrophils (Sadiku et al, 2021) 250, it occurs to me that
glycogen could also feasibly act as a damage-associated molecular pattern, or DAMP.
The immune system has multiple detection mechanisms of identifying dying or infected
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cells, including the release of certain molecules that would normally not be present
outside of the cell. Cytosolic DNA and secreted nuclear proteins are well established
DAMPs that can elicit an immune response. Similar to DAMPs are pathogen-specific
molecules, like lipopolysaccharide, which can distinguish self from foreign by the
immune system.
Therefore, glycogen, which to my knowledge has not be observed outside of the
mammalian cell, could act as signal or ligand indicating cellular apoptosis, following its
leakage into the extracellular space via porous membranes. To test this, microscopy
analysis on ccRCC cells induced to undergo programmed cell death could be performed
and visualized for extracellular glycogen. If glycogen is present, then the efficiency of
immune cell-mediated clearance of apoptotic ccRCC cells that either release or lack
glycogen could be addressed via co-culture experiments. This potential
immunomodulatory role of glycogen could also explain why we did not observe any
substantial effect on cell viability in vitro or in athymic xenograft models because there
was effectively no immune component in either system. Clinically, this could be
extremely interesting to know whether a tumor cell that has more glycogen would be
better recognized by the immune system and synergize with immunotherapies, which
are also highly studied in ccRCC (Motzer et al, 2020; Braun et al, 2021) 251,252.
Closing Remarks
In conclusion, we have shown that aspects of glucose metabolism can have context
specific roles in cancer. While not entirely positive, our results warrant further
investigation into the role of glucagon in liver cancer and glycogen in kidney cancer, as
discussed above, with a strong emphasis on translationally applicable models. I thank
everyone who has helped me with my research, as well as my mentor, Dr. Celeste
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Simon, for giving me the opportunity to pursue some of these less mainstream ideas. I
have learned a lot about scientific research, particularly the endless onslaught of
challenges, and how important is to strive towards honesty, commitment, and critical
thinking. Ultimately, I hope that I have provided a comprehensive (and comprehendible)
account of my research in the Simon lab and that any reader finds the information
useful.
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